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Repair of large bone defects remains a clinical challenge for orthopedic surgeons.  
Current treatment strategies such as autograft and allograft are limited by the amount of 
available tissue in the case of the former, and failure of revascularization effecting 
engraftment in the case of the latter.  Tissue engineering offers an alternative approach to 
this challenging clinical problem.  The general principle of tissue engineering for bone 
regeneration prescribes delivery of osteoinductive factors to induce an endogenous 
response within the host to repair a defect that will not normally heal.  One such tissue 
engineering approach is cell based therapy, and this is attractive in the cases of patients 
with a lack of endogenous osteoprogenitors cells due to volumetric loss of tissue/ageing. 
Stem cell therapy has emerged as a possible alternative to current treatment 
modalities, however many challenges to clinical translation remain.  Central to these 
challenges for bone tissue engineering are lingering questions of which cells to use and 
how to effectively deliver those cells.  The goal of this thesis was to elucidate more 
effective ways to enhance bone repair utilizing adult stem cells.  First, we investigated 
adipose derived stem cells (ADSCs) as a viable cell source for bone tissue engineering.  
Upon isolation, adipose derived stem cells are a heterogeneous population of multipotent 
cells predisposed to adipogenic differentiation.  We developed an enrichment protocol 
that demonstrated the osteogenic potential of ADSCs can be enhanced in a dose 
dependent manner with resveratrol, which had been demonstrated to up-regulate Runx-2 
expression.  This enrichment strategy produced an effective method to enhance the 
osteogenic potential of ADSCs while avoiding cell sorting and gene therapy techniques, 
thus bypassing the use of xenogenic factors to obtain an enriched source of 
 xxii 
osteoprogenitor cells.  This protocol was also used to investigate differences between 
human and rat ADSCs and demonstrated that rat ADSCs have a higher osteogenic 
potential than human ADSCs in vitro.   
 The second major thrust of this thesis was to develop an injectable hydrogel 
system to facilitate bone formation in vivo.  Both a synthetic and a naturally based 
polymer system were investigated, the results of which demonstrated that the naturally 
based alginate hydrogel was a more effective vehicle for both cell viability in vitro and 
bone formation in vivo.  Our results also demonstrated that despite the ability to increase 
the osteogenic potential of ADSCs in vitro with resveratrol treatment, this was 
insufficient to induce bone formation in vivo.  However, the inclusion of bone marrow 
mesenchymal stem cells (BMMSCs) in BMP-2 functionalized alginate hydrogels resulted 
in significantly greater mineralization than acellular hydrogels.  Finally, the effect of 
timing of delivery of therapeutics to a non-healing segmental bone defect in the femur 
was investigated.  We hypothesized that delivery of biologics after the initial 
inflammation response caused by injury to the host tissue would result in greater 
regeneration of tissue in terms of newly formed bone.  Contrary to our initial hypothesis, 
these experiments demonstrated that delayed implantation of therapeutics has a 
detrimental effect on the overall healing response.  It was, however, demonstrated that the 
inclusion of BMMSCs results in greater bone volume regenerated in the defect site over 
acellular hydrogels.     
In conclusion, this work has rigorously investigated the use of adipose derived 
stem cells for bone tissue engineering, and further produced an injectable hydrogel 
system for stem cell based bone tissue engineering.  This work also demonstrated that the 
 xxiii 
inclusion of adult stem cells, specifically BMMSCs, can enhance the regeneration 
response in a non-healing bone defect model relative to acellular hydrogels.
 
1 
CHAPTER 1: SPECIFIC AIMS 
 
INTRODUCTION 
 Current treatment modalities for management of large bone defects are limited 
and often ineffective.  Presently, the clinical gold standard for treatment of large 
segmental bone defects is autologous bone grafting.  This procedure, however, is severely 
constrained by a limited supply of available graft material, insufficient structural 
properties, and significant donor site morbidity (Bauer and Muschler 2000, Nandi, Roy et 
al. 2010).  An alternative treatment is processed bone allografts.  Again, this treatment 
possesses significant limitations, including an unacceptably high rate of post-implantation 
failure, largely attributable to the inability of the graft tissue to fully revascularize and 
remodel (Wheeler and Enneking 2005, Nandi, Roy et al. 2010).  Stem cell therapy has 
emerged as an attractive alternative to current treatment modalities.  Bone marrow 
mesenchymal stem cells (BMMSCs) are often employed as the cell source for bone tissue 
engineering applications; however, adipose derived stem cells (ADSCs) have also been 
shown to be osteogenic and offer the advantage of greater abundance than bone marrow 
mesenchymal stem cells.  The literature however suggests that the osteogenic potential of 
adipose derived stem cells may be inferior to bone marrow mesenchymal stem cells 
(Niemeyer, Fechner et al. 2010).  Thus a method to increase the osteogenic differentiation 
potential of the cells from adipose tissue may translate into increased bone formation 
when applied to a bone defect.  
 Gene therapy via viral transfection is a widely studied technique for controlling 
cell behavior, but has several drawbacks in the terms of clinical translation (Li and Huang 
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2000).  A pharmacological approach would provide a simpler method to promote 
differentiation along a given lineage.  Reports have shown that resveratrol is able to 
modulate both osteogenesis and adipogenesis (Backesjo, Li et al. 2006, Costa, Rohden et 
al. 2011).  The mechanism of action has been shown to be stimulation of the Sirt1 
pathway, which simultaneously promotes osteogenic differentiation and inhibits 
adipogenic differentiation.  Thus, adipogenesis is down-regulated in the presence of 
resveratrol by inhibition of peroxisome proliferator-activated receptor gamma (PPAR-γ), 
a key player in the control of adipocyte differentiation (Maroni, Brini et al. 2012).  
Furthermore, reports have shown that resveratrol treatment on mouse mesenchymal stem 
cells (MSCs) promoted osteogenic differentiation due to up-regulation of the Sirt1 
pathway which ultimately leads to increased Runt-related transcription factor 2 (Runx-2) 
expression stimulating osteogenic differentiation (Backesjo, Li et al. 2006).  These data 
demonstrate that resveratrol is a good candidate to promote osteogenic differentiation 
while simultaneously inhibiting adipogenesis in ADSCs, thereby increasing the utility of 
ADSCs for bone tissue engineering purposes.   
 Along with promotion of differentiation down a specific pathway, another 
criterion for cell based tissue engineering is a viable method of cell delivery.  We have 
shown that a majority of the cells initially implanted into a defect site lacking vascularity 
die within the first 72 hours post implantation (Appendix A).  As such, positive 
therapeutic outcomes for cell incorporation are difficult to obtain.  Hydrogels offer a 
potential avenue to increase the effectiveness of cell delivery and have advantages in 
several key areas specific for cell based tissue engineering.  First, hydrogels are able to 
facilitate cell adhesion via peptide incorporation.  As stem cells are adherent cells, 
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mimicking of the natural extracellular matrix (ECM) is vital to proper function of cells.  
Lack of adhesive peptides can cause stem cells to undergo anoikis leading to cell 
apoptosis.  Second, many groups have demonstrated that cell delivery also requires 
growth factor co-delivery to promote differentiation of the implanted cells (Awad, Quinn 
Wickham et al. 2004, Huang, Kaigler et al. 2004, Simmons, Alsberg et al. 2004).  
Encapsulation of growth factors into hydrogels has shown to be effective in inducing new 
tissue formation (Phelps, Landazuri et al. , Boerckel, Kolambkar et al. 2011, Kolambkar, 
Boerckel et al. 2011, Kolambkar, Dupont et al. 2011).  Hydrogels are able to serve as a 
barrier to the initial host inflammatory response, but eventually permit host cell invasion 
and vascularization to regenerate a functional tissue.  Finally, hydrogels may allow for 
the system to be injectable.  An injectable system would allow for the generation of larger 
pores facilitating mass transport, which may in turn increase cell viability.  Moreover, an 
injectable system would allow for delivery of stem cells at a delayed time point post 
injury creation.  This would avoid implanting the therapeutic during the initial 
inflammatory response, which may lead to greater implanted cell viability and an 
increase in active growth factor presentation to endogenous progenitor cells.  
The overall objective of this thesis was to evaluate the potential of adult stem cell 
sources to treat a critically sized non healing bone defect in the femur of the rat utilizing 
injectable, biologically functionalized hydrogels.  The central hypothesis was that 
inclusion of adult stem cells would lead to a greater bone regeneration response than 




SPECIFIC AIM I 
Evaluate pharmacological enrichment of rat and human adipose derived stem 
cells to promote osteogenic differentiation in vitro.  The objective of this aim was to 
develop an enrichment protocol using resveratrol to increase the osteogenic 
differentiation of ADSCs in vitro.  The working hypothesis was that pharmacological 
treatment of adipose derived stem cells with resveratrol would promote greater 
mineralized matrix production than that observed in untreated cells.  This was tested both 
in two dimensions (2-D) standard culture on tissue culture plastic and a three dimensional 
(3-D) differentiation system using a polymer scaffold consisting of poly (ε – 
caprolactone) (PCL) and collagen type I.  Rat and human ADSCs pretreated with varying 
concentrations of resveratrol in 3-D culture were assessed for mineralized tissue 
formation via micro computed tomography (micro-CT) imaging over a 12 week time 
course.  Finally, we tested concurrent treatment of resveratrol and bone morphogenetic 
protein-2 (BMP-2) in both the 2-D and 3-D differentiation systems.  The outcomes of this 
Specific Aim are discussed in Chapter 3. 
 
SPECIFIC AIM II 
Evaluate synthetic and naturally based hydrogels as an injectable cell delivery 
system in terms of cell viability and subcutaneous osteogenic differentiation.  The 
objective of this aim was to evaluate the use of poly-ethylene glycol (PEG) and alginate 
hydrogels to serve as an injectable hydrogel for bone tissue engineering.  The working 
hypothesis was that extrusion of the hydrogel via injection would facilitate greater cell 
viability in vitro than traditionally mold cast hydrogels, ultimately leading to greater 
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ectopic mineralization in vivo with the incorporation of BMP-2 when applied to a 
subcutaneous mineralization model.  The hypothesis was first tested using PEG hydrogels 
and a histomorphometric analysis of green fluorescent protein (GFP) expressing ADSCs 
and BMMSCs in vitro. The amount of GFP expressing cells and the amount of dead cells 
was quantified after 14 days in culture.  We next tested the PEG system for in vivo 
mineralization with adult stem cell and BMP-2 co-delivery and found limited mineralized 
tissue due to lack of resorption of the PEG hydrogel.  Therefore irradiated and oxidized 
irradiated alginate hydrogels were then tested as cell delivery vehicles.  Cell viability was 
assessed over a 14 day time course using a histomorphometric analysis and confirmed via 
DNA content.  In vivo ectopic mineralization was then evaluated in a subcutaneous 
implant model, with the presence of implanted cells assessed after 8 weeks.  The 
outcomes of this Specific Aim are discussed in Chapter 4. 
 
SPECIFIC AIM III 
 Determine the effect of timing of therapeutic delivery on the bone regeneration 
process in a non-healing bone defect model.  The objective of this aim was to determine 
whether delaying the time a therapeutic is delivered to a bone defect has an effect on the 
amount of tissue regenerated in a critically sized femoral defect.  The working hypothesis 
was that delaying the implantation time from the creation of the defect would lead to 
greater mineralized tissue volume by avoiding the initial host inflammation response.  To 
evaluate this hypothesis, we first evaluated the host tissue invasion into empty defects 
over a 14 day time course to assess the amount of tissue and types of cells present in the 
defect site.  Next, we attempted to deliver both acellular and cell loaded BMP-2 
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functionalized alginate hydrogels percutaneously into the segmental defect both at the 
time of the creation of the defect and 14 days following the creation of the defect.  
Inaccurate delivery and lack of bone volume resulted in a follow up study where a second 
minor surgery was performed allowing the defect site to be visible to the surgeon.   
Constructs were implanted immediately and 7 days after the creation of the defect.  The 
results of this Specific Aim are discussed in Chapter 5.   
 
SIGNIFICANCE 
 This thesis presents a significant contribution to the field of bone tissue 
engineering utilizing adult stem cell based therapeutics.  The effectiveness of adult stem 
cells from both adipose tissue and bone marrow were assessed in multiple types of 
hydrogels for bone tissue engineering, and further, the effect of timing of delivery of 
therapeutics was evaluated.  This work produced the following outcomes: 1) Produced a 
pharmacological enrichment strategy to increase the in vitro differentiation potential of 
adipose derived stem cells from both human and rat donors, 2)  Demonstrated differences 
in PEG and alginate based hydrogels in terms of maintaining cell viability in vitro and 
bone formation in vivo, 3) Demonstrated that delaying the delivery of therapeutics 
inhibits the amount of regenerated bone tissue in a non-healing bone model, 4) 
Demonstrated that inclusion of BMMSCs causes a significant increase in the amount of 
mineralized tissue over comparable acellular hydrogels. 
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CHAPTER 2: LITERATURE REVIEW 
 
BONE STRUCTURE AND FUNCTION 
Bone Function 
 Bone is one of the primary organs constituting the musculoskeletal system.  It 
serves a variety of physiological functions in vertebrates including: ion homeostasis, 
particularly in the case of calcium which is important for cell function and signaling; 
production of hematopoietic precursors in the medullary cavities, giving rise to red and 
white blood cells; and the site of mesenchymal precursors, which mobilize and repair 
injured sites in the musculoskeletal system (Marks and Popoff 1988, Cohen 2006).  In 
addition to its physiological functions, bone also serves as the major structural 
component of the musculoskeletal system.  Bone serves as the protecting structure for the 
vital organs including the heart and lungs, as well as the central nervous system 
comprising the brain and spinal cord.  Bone also is the anchoring point for muscles, 
tendons, and cartilage, giving rise to articulating joints providing movement (Baron 
1993).  Injury or loss of bone tissue inhibits the ability for joints to articulate properly, 
motivating the need for treatment options for bone repair.   
Types of Bones 
 Bone has a hierarchal organization consisting of the whole bone level, the 
apparent bone level, and the ultrastructural level (Weiner 1998).   On the whole bone 
level, there are five major categories of bones generally based on their shape or function 
and categorized as flat, short, long, irregular, and sesamoid bones (Buckwalter 1996).  
Flat bones reside primarily in the cranium, but are also found in the shoulder region and 
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pelvic region.  These bones generally have the characteristic of a small thickness relative 
to their length and width.  Short bones are characterized by having relatively the same 
dimensions in all directions, and are primarily found in the hands and feet.  Irregular 
bones are normally categorized as such due their specialized geometry suited for their 
specific function.  Examples of irregular bones are vertebrae, the mandible, and the 
sacrum in the pelvic region.  Similarly, sesamoid bones are categorized as such due to 
their function.  Sesamoid bones are embedded in tendon tissue and serve as structural 
component to maintain constant moments across joints.  The typical example of a 
sesamoid bone is the patella in the knee.  Finally, long bones are defined as bones with a 
length greater than their width.  These are the primary bones comprising the limbs of 
most vertebrates.  Long bones are defined by three regions: the diaphysis, metaphysis, 
and epiphysis, and are delineated relative to their position of the epiphyseal plate.  The 
epiphyseal plate, or growth plate, is an area of cartilaginous tissue responsible for 
elongation of long bones during growth and development.  The epiphyses are located on 
both ends of bone and are covered by cartilage to facilitate articulation of joints.  The 
metaphysis is the area of bone between the epiphysis and diaphysis and the region that 
contains the epiphyseal plate.  The diaphysis is the center of long bones and contains the 
medullary cavity which is the site of hematopoiesis and progenitor cells (Alberts 2002).   
Cortical and Trabecular Bone 
On the apparent bone level, the primary classifications of structures of bone are 
cortical bone and trabecular bone (Buckwalter 1996, Buckwalter 1996).  Cortical bone is 
described as a highly compact tissue with limited porosity.  Cortical bone is comprised of 
a series of neighboring osteons.  Osteons in turn are comprised of lamellae with 
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interconnecting canaliculi.  At the center of the osteon is a channel where osteocytes 
(described below) reside called lacunae.  Lacunae form the Haversian system that allows 
signaling between osteons and ultimately allows bone to remodel to stimuli.  These 
Haversian canals are generally oriented parallel to the diaphyseal surface (Alberts 2002).  
The highly compact nature of cortical bone gives rise to its primary function to bear 
mechanical loads.  Conversely, trabecular bone, or cancellous bone, is often termed 
‘spongy’ and is noted by its rod and plate structure, giving rise to large interconnected 
cavities.  Trabecular bone is found in the ends of long bones and inside the medullary 
cavity of long bones.  It is highly vascularized, and is characterized by its relative lack of 
density compared to cortical bone.  The vascularity along with its high surface area due to 
its plate and rod structure results in trabecular bone being primarily responsible for 
metabolic and physiologic functions such as ion homeostasis (Marks and Popoff 1988).   
Bone Extracellular Matrix 
The ultra-structural level of bone consists of the bone extracellular matrix (ECM) 
and the cellular components of bone.  The extracellular matrix of bone consists of two 
phases: an organic component containing connective proteins, proteoglycans, and growth 
factors; and an inorganic component comprised of mineral ions mainly in the form of 
hydroxyapatite.  The primary component of the organic phase of bone is collagen I 
comprising 90% of the organic phase of bone ECM (Buckwalter 1996).  Collagen I has a 
triple helical structure giving it high tensile strength (Patino, Neiders et al. 2002).  The 
inorganic component consists predominately of hydroxyapatite and is noted by its high 
content of calcium and phosphate groups, which serve as reservoirs for ion homeostasis.  
The collagen network forms nucleation sites for mineral precipitation, giving rise to both 
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the tensile and compressive properties of bone tissue.  The other components of the bone 
ECM include growth factors responsible for maintenance of bone structure.  One of the 
most studied family of growth factors are the bone morphogenetic proteins (BMPs) 
described further below (Wozney 2002).   This family of growth factors has been shown 
to be highly potent in their osteoinductivity and induce bone formation in both orthotopic 
and ectopic sites.  As such, this family of growth factors has been shown to be effective 
in the generation of alternative strategies to regenerate bone (Luca, Rougemont et al. , 
Knippenberg, Helder et al. 2006, Usas, Ho et al. 2009).   
Bone Cells and Bone Remodeling 
 Depositing and remodeling the bone extra cellular matrix are the cells residing in 
bone tissue.  The main cell types in bone are osteoblasts, osteoclasts, and osteocytes 
(Marks and Popoff 1988).  Osteoblasts are derived from osteoprogenitor cells located in 
the periosteum and the medullary cavity. These osteoprogenitor cells will begin to 
differentiate when presented with growth factors such as BMPs.  As the osteoprogenitors 
mature into osteoblasts, they will begin to express and secrete proteins such as collagen 
type I, osteocalcin, and alkaline phosphatase.  Once mature, osteoblasts are located on the 
surface of bone and when depositing new tissue, or osteoid, align themselves with other 
osteoblasts to generate a newly formed surface.  Osteoid is an unmineralized matrix of 
organic components, mainly collagen type I, but also contains chondroitin sulfate and 
osteocalcin (Bono and Einhorn 2005).  This large secretion of proteins is made possible 
by the osteoblasts having a large endoplasmic reticulum and Golgi apparatus, which are 
two of the primary organelles responsible for protein export out of the cell.  As the 
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osteoid matures, it serves as the nucleation point of the inorganic mineral phase of bone 
matrix.   
 As osteoblasts deposit matrix, some become entrapped in the mineralized tissue.  
Once entrapped, these cells will slow down their metabolic function and reduce their 
protein machinery to become osteocytes.  Osteocytes are located in the lacunae described 
previously at the apparent bone level.  Osteocytes are responsible for the maintenance of 
the bone tissue and provide paracrine signaling to active osteoblasts, thus regulating bone 
formation.  This is achieved through canaliculi which are cytoplasmic protrusions from 
the cell body that allow nutrient and waste transport via gap junctions (Marks and Popoff 
1988).  When an osteocyte undergoes apoptosis, it will release receptor activator of 
nuclear factor kappa-B ligand, or RANKL, which will recruit osteoclasts to the bone 
tissue around the osteocyte to promote bone resorption (Kurata, Heino et al. 2006).  As a 
controller of osteoblast and osteoclast activity, the osteocyte is the critical cell in 
regulating bone turnover.   
 The final primary cell type found in bone is the osteoclast.  As mentioned above, 
the osteoclast is responsible for resorption of bone.  Osteoclasts are derived from 
monocytes and upon stimulation from RANKL will undergo fusion of precursor cells to 
form a multinucleated cell (Suda, Kobayashi et al. 2001). The mechanism of resorption is 
through proton pumps, which create an acidic environment on the bone surface to break 
down the organic phase of the bone matrix (Suda, Kobayashi et al. 2001).  To increase 
the surface area of the resorption site, the osteocyte has a folded membrane on the bone 
surface to form the resorptive pit (Howships lacuna).   
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 In adults, bone is remodeled and turned over at a rate of approximately 10% per 
year (Fernández-Tresguerres Hernández-Gil 2006).  The signaling between osteoblasts, 
osteocytes, and osteoclasts is responsible for this bone turnover.  Once osteocytes 
undergo apoptosis, they will activate osteoclast precursors to differentiate into mature 
osteoclasts and resorb the bone in the area.  Once resorbed, osteoblasts will hone to the  
site and deposit new osteoid thus creating new bone tissue (Feng and McDonald 2011).  
This system of bone turnover is carefully balanced, and tipping of the scales to favor 
resorption or deposition results in poor quality bone with diminished mechanical 
properties.  The two most prominent pathological conditions that arise from an imbalance 
in bone remodeling are osteoporosis, where resorption outpaces deposition, and 
osteopetrosis, where deposition outpaces resorption (Feng and McDonald 2011).   
 In addition to the primary cell types discussed previously, there are also 
populations of cells specific to certain areas of bone.  As mentioned previously, the 
medullary cavity is the site of hematopoiesis and contains precursors for blood cells.  In 
addition to hematopoietic precursors, the medullary cavity also contains mesenchymal 
stem cells which are osteoprogenitor cells that differentiate to become osteoblasts.  
Another site for osteoprogenitor cells is the periosteum (Kojimoto, Yasui et al. 1988, 
Iwasaki, Nakahara et al. 1995, Perka, Schultz et al. 2000).  The periosteum is a 
membrane of connective tissue that covers the outside of cortical bone in long bones, and 
contains its own population of osteoprogenitor cells that have been shown to be important 
in fracture repair.  Cells isolated from the periosteum have been incorporated into 
biomaterials to heal calvarial defects in rodents (Breitbart, Grande et al. 1998).  A similar 
membrane is found coating the inside of the medullary cavity and is termed the 
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endosteum, however this is not normally used a as a source for progenitor cells given its 
location and difficulty in obtaining cells from that tissue.   
BONE DEVELOPMENT AND MATURATION 
 There are two primary mechanisms for bone development: endochondral and 
intramembranous ossification (Ornitz and Marie 2002, Mackie, Ahmed et al. 2008).  
Endochondral ossification is denoted by the presence of a cartilaginous matrix prior to 
mineralization.  This type of ossification occurs in long bones and short bones.  In this 
method of development, progenitor cells condense and differentiate into chondrocytes, 
which then produce a cartilage template of the developing tissue.  Mineralization and 
growth of the tissue occurs in the ‘bone collar’, which is a region rich in proliferating 
chondrocytes (Mackie, Ahmed et al. 2008).  The proliferating chondrocytes continue to 
form new matrix, until cells begin to degrade the chondrogenic material.  The cells will 
then undergo apoptosis, leaving a void where blood vessels will invade.  Once 
vascularized, osteoprogenitors are recruited to the cartilaginous matrix and begin to 
differentiate into osteoblasts and mineralize the cartilaginous template.  This process 
continues outwards from the bone collar thus elongating the developing tissue.  
Eventually two areas of growth develop that continue this process and become the 
epiphyseal plates as described previously.  In the developing tissue the deposited osteoid 
is unorganized and is characterized as woven bone.  Over time, the deposited osteoid 
tissue is continually remodeled into a compact structure and becomes lamellar bone.   
 Intramembranous ossification occurs without the development of a cartilaginous 
template.  In this method of ossification, there are regions of dense progenitor cells that 
form multiple ossification centers.  These ossification centers grow out radially via bone 
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spicules and fuse together to form a mature bone structure.  The bone spicules follow 
areas that are vascularized, and osteoblasts are recruited via the vasculature and continue 
to deposit more osteoid.  The most common bones that undergo intramembranous 
ossification are the flat bones in the cranium, the scapula in the shoulder, and the bones 
that form the pelvic region.   
 Despite the two mechanisms of bone development there are common traits 
between both types.  First, both types rely on progenitor cells to differentiate into 
osteoblasts and deposit osteoid.  Second, both tissues rely on vascular invasion to recruit 
osteoprogenitor cells to form bone matrix.  In common fracture healing, it is an interplay 
of both methods that results in fully regenerated bone tissue (González, Cerrolaza et al. 
2009).   
 
BONE FRACTURE AND NON-HEALING DEFECTS 
Bone Fracture and Healing Response 
 The cellular components of bone engender its ability to heal itself in cases of 
fracture.  In the case of a simple fracture, there are three phases that typically occur in 
order to form a fully healed tissue.  These phases are the reactive phase, the reparative 
phase, and the remodeling phase (Einhorn 1998).  The reactive phase begins with 
bleeding occurring at the fracture site.  The pooling of blood eventually forms a fibrin 
clot defined as a hematoma.  The development of the hematoma is followed by cellular 
death and the formation of granular tissue.  With the formation of the granular tissue, the 
reparative phase initiates.  Cells from the neighboring periosteum begin to form a 
cartilaginous matrix on both ends of the fracture.  Once these ends meet, a fracture callus 
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is formed.  Recruitment of osteoprogenitor cells from the medullary cavity and the 
periosteum occurs, and the cells begin to undergo endochondral ossification forming a 
woven bone structure.  During this stage of repair, much of the bone resembles trabecular 
bone in terms of mineral content and composition.  The final phase of fracture healing is 
the remodeling phase.  This phase is noted by osteoclast resorption of the newly formed 
trabecular bone, followed by the deposition of compact cortical bone by osteoblasts 
ultimately resulting in functionally regenerated tissue.   
Non-healing Bone Defects and Clinical Implications 
 In severe cases of fracture the normal repair process is unable to restore function.  
This is also true in the case of volumetric bone loss, such as in the case of traumatic 
injury or in tumor resection.  Loss of progenitor cells or damage to surrounding tissue can 
limit the endogenous healing capacity of the patient, resulting in nonunion of the defect 
(Bruder and Fox 1999).  There is a large clinical for effective treatment strategies for 
such defects.  According to the United States Bone and Joint Decade, musculoskeletal 
conditions are the most commonly reported health conditions in U.S. citizens, occurring 
in roughly 48% of the population.  Beyond the associated physical afflictions is the 
enormous financial burden - $849 billion in 2004 alone (Decade 2009).  In addition, these 
injuries are of specific concern to the United States Armed Forces as trauma to the 
extremities remains the most prevalent combat injury of troops admitted to the theater 
(Baer 2004).  Bone grafting procedures have an annual occurrence greater than 500,000 
resulting in a cost greater than $2.5 billion in the United States alone (Laurencin, Khan et 
al. 2006).    
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Current clinical treatment modalities for management of large bone defects are 
limited and often ineffective.  The clinical gold standard for treatment of large segmental 
bone defects is autologous bone grafting.  This procedure, however, is severely 
constrained by a limited supply of available graft material, insufficient structural 
properties, and significant donor site morbidity.  Another often-employed treatment is 
allograft tissue obtained from cadavers.  Again, this treatment possesses significant 
limitations, including an unacceptably high rate of post-implantation failure.  This is 
largely attributable to an inability of the graft tissue to fully revascularize and remodel 
leading to decreased integration of the graft to the host tissue.  There are also additional 
concerns with regard to disease transmission and immune rejection with allograft use 
(Nandi, Roy et al. 2010).  The occurrence of refracture varies depending on the size of 
the graft, but has been reported to be as high as 25-35%  (Sorger, Hornicek et al. 2001).  
As such, alternative treatment strategies are warranted to address the shortcomings of 
current treatment modalities. 
 
CELL BASED TISSUE ENGINEERING STRATEGIES FOR  
BONE REGENERATION 
Premise of Tissue Engineering 
 Tissue engineering offers an attractive alternative to current clinical treatment 
methods as stem cells, scaffolds, and growth factors can be delivered to augment the host 
response to heal critically sized defects.  In particular, cell based therapies have the 
potential to alleviate the use of grafts from host tissue and allogeneic tissue sources 
(Bruder and Fox 1999, Kimelman, Pelled et al. 2007).  Ideally, a cell-based tissue 
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engineering approach would incorporate the use of an autologous cell source and a 
biodegradable scaffold to allow for graft incorporation and eventual tissue remodeling in 
vivo.  Autologous cell therapies eliminate the risk of graft rejection due to an immune 
response.  However, a body of work suggests that stem cells from the mesenchymal 
lineages have immune privilege such that they could be transplanted allogeneically 
without rejection (Dominici, Le Blanc et al. 2006, Niemeyer, Kornacker et al. 2007).  
Incorporation of a resorbable scaffold would provide short-term retention of therapeutics 
while facilitating host tissue invasion in the long term.  In addition, co-delivery with 
growth factors would promote recruitment of host cells to a defect site as well as promote 
the differentiation of implanted cells.  These tools allow for a large assortment of 
potential strategies to address many developmental diseases and traumatic injuries. 
Scaffolds and Biomaterials for Bone Tissue Engineering 
 Scaffolds for bone tissue engineering can be used for mechanical support, a 
delivery vehicle for biologics, a conduit for host tissue invasion and remodeling, or any 
combination thereof.  As such scaffolds should be biocompatible and allow for cellular 
attachment and differentiation.  In terms of mechanics, the scaffold can be tailored to its 
environment and this may dictate the choice of material used.   When the goal is to have 
completely remodeled host tissue, the scaffold must be biodegradable to allow the host 
tissue to remodel and degrade the scaffold.  This can be achieved by incorporating a 
protease sensitive component that will allow the material to be enzymatically degraded 
by cells in the defect.  Conversely, the ultimate outcome of using a rigid scaffold may be 
to integrate with the surrounding tissue while allowing new tissue growth inside the 
scaffold.  This is generally the approach when using ceramics as the scaffold.  The 
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advantage of using rigid scaffolds like ceramic is that the material properties are similar 
to native cortical bone, thus allowing mechanics that will not stress shield the native 
tissue and cause further resorption (Byrne, Lacroix et al. 2007).  Common material 
categories for bone tissue engineering and their relative properties to native bone tissue 
are displayed below (Amini, Laurencin et al. 2012). 
 
Figure 2.1 - Mechanical properties of common scaffold choices for bone tissue 
engineering relative to the mechanical properties of trabecular and cortical bone. 
 
 Ceramic materials for bone tissue engineering are generated by soaking a sponge 
with a high mineral content solution such as hydroxyapatite.  The sponge is then sintered 
at an extremely high temperature to make a glass-like material (Teixeira, Fernandes et al. 
2010).  To increase cellular attachment, many ceramics will be coated with proteins such 
as collagen I or fibronectin.  An alternative to a largely ceramic scaffold is the inclusion 
of ceramic particles into a polymer scaffold.  Beta tri-calcium phosphate (β-TCP) 
particles can be used in conjunction with a polymer to create a composite material 
mimicking the organic and inorganic extracellular matrix of bone.  Cao created a 
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composite material of poly-glycolic acid (PGA) and β-TCP particles and implanted them 
into a femoral defect.  By varying the ratio of PGA to β-TCP the amount of bone formed 
in the defect was modulated and shown to obtain a mineral density comparable to native 
hydroxyapatite (Cao and Kuboyama 2010).    
Polymer scaffolds for bone tissue engineering can be made of both natural and 
synthetic materials.  The most commonly employed natural polymers employed are 
collagen, fibrin, alginate, and silk fibroin (Luca, Rougemont et al. , Karageorgiou, Meinel 
et al. 2004, Yang, Bhatnagar et al. 2004, Fini, Motta et al. 2005, Murphy, Haugh et al. 
2010, Boerckel, Kolambkar et al. 2011, Kolambkar, Boerckel et al. 2011, Kolambkar, 
Dupont et al. 2011, Sheyn, Kallai et al. 2011).     With the high collagen content found in 
bone, collagen is an ideal candidate for bone tissue engineering.  However, natural 
polymers, including collagen scaffolds, have weak mechanical properties, and thus 
necessitate the use of fixation devices in the early healing process.  Cross-linking can 
help increase the mechanical strength of the polymer, but still is not adequate to bear 
loads immediately.  Collagen scaffolds are currently used clinically with BMP-2 for 
spinal fusion treatment.  In this procedure, a collagen sponge is soaked in BMP and 
placed between vertebrae to fuse them together and recapitulate mechanical integrity.  
Fibrin is able to be cross-linked to form a gel that can then be injected into defect sites 
and has demonstrated promotion of bone formation.  Fibrin has also been shown to be 
highly favorable for cell viability, and cell mobility and attachment can be controlled by 
varying the fibrin concentration (Hale, Goodrich et al. 2012).   Sheyn showed that 
incorporation of genetically modified adult stem cells into a fibrin gel is able to double 
the amount of bone volume formed in a vertebral bone defect model (Sheyn, Kallai et al. 
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2011).  Alginate has similarly been shown to be an effective natural polymer for bone 
tissue engineering, and is discussed in more detail below. 
Synthetic materials offer high plasticity in formulation, ultimately allowing the 
material to be tailored to a specific application.  Synthetic polymers can be functionalized 
by including cell adhesion peptides, growth factors, and protease sensitive motifs to 
facilitate enzymatic degradation.  There are a wide range of synthetic polymers available 
for tissue engineering, including poly-lactic acid (PLA), PGA, poly-(ε-caprolactone) 
(PCL), and poly-ethylene glycol (PEG) (Majola, Vainionpää et al. 1991, Breitbart, 
Grande et al. 1999, Burdick 2002, Hu, Zhang et al. 2003, Richardson, Curran et al. 2006, 
Dupont, Sharma et al. 2010).  A potential deficit of using synthetic polymers such as 
PLGA and PGA based materials is that when degraded the products formed can be acidic 
thereby inducing an inflammatory response or having a detrimental effect on the function 
of the cells surrounding the material. 
An effective strategy for using both natural and synthetic polymers for cell-based 
therapies is to form a hydrogel.  A hydrogel is characterized by its high water content 
with insoluble polymers that form a cross-linked network to retain a shape.  The high 
water content gives the hydrogels mechanical properties similar to soft tissue and in itself 
is insufficient to maintain the mechanical loads in a segmental defect (Park 2011).  As 
such, a fixation device needs to be employed in conjunction with the hydrogel for load 
bearing sites.  Our lab uses a guided bone regeneration technique that utilizes an internal 
fixation plate, a membrane, and a hydrogel to treat femoral segmental defects.  Guided 
bone regeneration is defined as the use of a membrane along the periosteal surface to 
control the area of bone formation (Kim, Jeong et al. 2005, Dahlin, Johansson et al. 
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2012).  The membrane employed in our segmental defect model is a PCL nanofiber mesh 
tube and this is placed between the ends of the defect site.  Once placed, a hydrogel with 
osteoinductive factors is injected filling the void.  Two hydrogels that will be utilized in 
this thesis are both a synthetic PEG hydrogel and a naturally based alginate hydrogel 
using the guided bone regeneration technique.   
While PEG has been used as a cell and drug delivery vehicle in various tissue 
engineering applications, its use in bone regeneration has been limited.  PEG has no cell 
attachment domains, necessitating cell attachment motifs be tethered to the PEG 
backbone.  A report has shown that functionalizing PEG with an RGD cell attachment 
peptide sequence, which mimics the cell adhesion site of fibronectin, leads to cell 
spreading in the hydrogel (Salinas and Anseth 2008).  Comparison of soluble and 
tethered fibronectin sequences showed that tethering of a fibronectin sequence leads to 
greater cell spreading than soluble, as the cell is able to adhere to the PEG network versus 
a freely floating RGD sequence.  Further, the amount of cell spreading was determined to 
be dose dependent as greater cellular area was observed with increased RGD 
concentration.  Cellular attachment and spreading allows for cellular deposition of extra 
cellular matrix molecules, thus leading to the possibility of mineralized matrix within the 
hydrogel.   This has been demonstrated by Burdick in which mineralized matrix was 
found on PEG hydrogels with tethered RGD (Burdick 2002).  Betz demonstrated that 
modification of the PEG hydrogel to generate larger pore sizes resulted in increased 
osteoblastic gene activity and protein production by human mesenchymal stem cells 
(Betz, Yeatts et al. 2010).   These studies demonstrate that PEG hydrogels are a viable 
osteoinductive delivery vehicle for bone tissue engineering applications. 
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Alginate has been shown to be an effective delivery vehicle for biologics for bone 
tissue engineering.  Alginate is a polysaccharide derived from seaweed, and its properties 
can be manipulated by varying the concentration of its two primary components, 
mannuronic and guluronic acid.  The backbone of alginate is highly negative which 
allows multiple chains to be cross-linked with a divalent cation such as calcium or 
magnesium.  Further, the backbone chain of alginate can be manipulated with cell 
attachment motifs to facilitate cell adhesion and alter cell differentiation (Rowley and 
Mooney 2002, Comisar, Kazmers et al. 2007).  Kolambkar demonstrated that when 
paired with BMP-2, alginate hydrogels are able to heal critically sized femoral segmental 
defects in rodents (Kolambkar, Boerckel et al. 2011, Kolambkar, Dupont et al. 2011).  
Mechanical testing showed that the regenerated bone tissue was not significantly 
different from intact bone, demonstrating successful functional repair of the defect.   
Boerckel followed this study with a dose dependency study demonstrating that the dose 
of BMP-2 affects the amount of regenerated tissue.  Further, it was demonstrated in the 
rat that the alginate and BMP-2 system resulted in greater bone formation than the 
clinically used collagen sponge with an equal amount of BMP-2 (Boerckel, Kolambkar et 
al. 2011). 
Growth Factors for Bone Tissue Engineering 
 As many of the previously highlighted studies show, growth factor delivery is a 
central tenant for bone tissue engineering.  The most common growth factors employed 
for bone tissue engineering are bone morphogenetic proteins, or BMPs.  BMPs were first 
discovered in 1965 when Marshall Urist implanted decellularized and decalcified 
allografts into intramuscular pockets and noted their osteoinductivity (Urist 1965).  The 
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proteins responsible were later identified and termed bone morphogenetic proteins.  Over 
20 BMPs have been identified and have been shown to be instrumental in guiding tissue 
development throughout the body.  The two most commonly used for bone tissue 
engineering are BMP-2 and BMP-7, belong to the transforming growth factor beta (TGF-
β) superfamily (Wozney 2002).  BMPs react with specific receptors on the cell surface 
initiating a signaling cascade.  Dimerization of type I and type II TGF-β receptors 
activate the SMAD signaling cascade.    SMADS are a family of intracellular proteins 
that specifically transduce extracellular signals from TGF-β to the nucleus initiating 
transcription of osteogenic genes.  Runx-2 is one of these up-regulated genes, and is 
known as the master control switch for osteogenic differentiation.  As such, this makes 
BMP delivery an effective tool for bone tissue engineering. 
 As mentioned previously, BMP-2 and BMP-7 have been widely studied as 
osteoinductive factors and are currently used clinically for spinal fusion.  Both proteins 
have been approved by the FDA for use in grafting procedures.  The use of BMPs has 
grown from .69% of all fusions in 2002 to 24.89% of all fusions in 2006 (Cahill, Chi et 
al. 2009).  Medtronic developed its Infuse product which takes a bovine type I collagen 
sponge and soaks it in a high concentration of BMP-2 solution before being implanted.  
Stryker Biotech developed both a putty and an implant based on BMP-7 incorporation for 
lumbar spine fusion as well as nonunion of bone fractures.  Despite their rising use in the 
clinic, reports have shown that supraphysiologic doses of BMP can result in poor bone 
quality (Razzouk and Sarkis 2011, Yu, Schindeler et al. 2012).  The potency of BMPs 
results in large volumes of bone forming quickly and the tissue may not be able to be 
maintained long term.  In addition, BMP use can cause adverse complications in wound 
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healing and have also been associated with a surge in costs of fusion procedures 
(Razzouk and Sarkis 2011).  As such, reducing the amount of BMP needed for restoration 
of a defect may lead to better clinical outcomes.  One such way to reduce BMP dosage is 
via stem cell co-delivery. 
Stem Cell Sources for Bone Tissue Engineering 
 Stem cells are classified by their potency, or ability to differentiate into multiple 
tissues.  The fertilized egg represents a totipotent cell and gives rise to all of the tissues 
found in an organism.  Pluripotent cells have the capability of differentiation into any of 
the three germ layers: the endoderm which forms the inner linings of organs such as the 
lungs and gastrointestinal tract; the mesoderm which forms the muscle, bone, and blood 
cells; and the ectoderm which forms the nervous system and epidermal tissues such as 
skin.  The most commonly referenced pluripotent cells are embryonic stem cells (ESCs) 
derived from the inner cell mass of a blastocyst.  The harvesting of the inner cell mass 
results in the destruction of the embryo, giving rise to ethical concerns about their use for 
tissue engineering (de Wert and Mummery 2003).  Moreover, the generation of 
osteogenic cells from ESCs is difficult as the ESC population is often heterogeneous and 
possibly tumorogenic (Arnhold, Klein et al. 2004, Amini, Laurencin et al. 2012).  A 
recent report, however, did suggest that BMP-2 laden scaffolds seeded with ESCs are 
capable of forming mineralized tissue in vivo (Levi, Hyun et al. 2012).  That study further 
demonstrated that fibroblasts genetically modified to a pluripotent state are also able to 
form bone in vivo under the direction of BMP-2.  These cells are termed induced 
pluripotent stem cells (iPS cells).  A report also suggests that a cocktail of proteins may 
also be able to induce the pluripotent state, thereby alleviating the need for viral vectors 
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(Zhang, Li et al. 2012).  Both these techniques are in their nascent stage and their 
evaluation for in vivo bone regeneration is limited.  Fetal stem cells have also been 
investigated as a potential cell source for bone tissue engineering.  Stem cells from 
amniotic fluid have been demonstrated to be osteogenic both in vitro and in vivo (Peister, 
Porter et al. 2008, Peister, Deutsch et al. 2009, Dupont, Sharma et al. 2010, Peister, 
Woodruff et al. 2011).  Reports suggest these cells retain much of the potency of 
embryonic stem cells, in that they are able to undergo differentiation into the three germ 
layers (De Coppi, Callegari et al. 2007, Tsai, Hwang et al. 2007, Hauser, De Fazio et al. 
2010, Antonucci, Stuppia et al. 2011, Park, Shim et al. 2011).   
The next level in terms of potency is multipotent cells.  These cells are more 
generally referred to as adult stem cells as these progenitor cells can be isolated from 
fully developed adult tissue.  For bone tissue engineering, the most common adult stem 
cells used are mesenchymal stem cells.  These cells are found in multiple tissues 
including bone marrow, adipose tissue, and muscle tissue.  The cells from all three 
sources exhibit similar cell surface marker profiles despite their origin from different 
tissues, and are capable of differentiating down the mesodermal lineages of bone, muscle, 
cartilage, and fat (Deasy, Jankowski et al. 2001, Kern, Eichler et al. 2006).   A similar 
source of mesenchymal stem cells is umbilical cord blood (Erices, Conget et al. 2000, 
Xu, Meng et al. 2010).   Mekala was able to demonstrate that cells derived from 
umbilical cord are able to undergo osteogenic differentiation on PLGA scaffolds, 
implicating the possibility of their use for bone tissue engineering (Mekala, Baadhe et al. 
2013).  The two cell types studied in this thesis are bone marrow mesenchymal stem cells 
and adipose derived mesenchymal stem cells. 
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Figure 2.2 – Mesenchymal stem cells and differentiation pathways for multiple adult 
tissues of the mesoderm (Firth and Yuan 2012).   
 
Bone Marrow Mesenchymal Stem Cells for Bone Tissue Engineering 
 Cells from bone marrow were first shown to be multipotent in 1924 when 
Alexander Maximow developed his theory that all blood cells come from one precursor 
hematopoietic cell (Maximow 1924).  Similarly, another population of cells found in the 
bone marrow was shown to be multipotent.  Bone marrow mesenchymal stem cells were 
first identified by Friedenstein and Owen (Friedenstein, Piatetzky et al. 1966, Owen 
1988).  Arnold Caplan developed a method to isolate and expand BMMSCs while 
maintaining their potency (Caplan 1991).  It was later demonstrated that MSCs from bone 
marrow were capable of differentiating into multiple phenotypes including bone, 
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cartilage, muscle, adipose, and connective tissues if given certain cocktails of cytokines 
to induce their commitment to a lineage (Pittenger, Mackay et al. 1999).  It has also been 
shown that differentiation of BMMSCs can be controlled by the stiffness of the substrate 
they are cultured on, demonstrating a mechanical component to the differentiation 
pathway (Pek, Wan et al. 2010).  Given their location in the bone marrow, BMMSCs 
seem an intuitive choice for a cellular component in a tissue engineering approach to 
bone regeneration.  When incorporated into biomaterials, it has been shown that inclusion 
of BMMSCs can increase the rate and overall volume of bone tissue formed (Amini, 
Laurencin et al. 2012).  BMMSCs have been utilized in a variety of bone defect models 
including segmental defects, calvarial defects, and fusion of spinal vertebrae (Kadiyala, 
Jaiswal et al. 1997, Shang, Wang et al. 2001, Blum, Barry et al. 2003, Hasharoni, 
Zilberman et al. 2005, Gan, Dai et al. 2008, Dupont, Sharma et al. 2010).   
Adipose Derived Mesenchymal Stem Cells for Bone Tissue Engineering 
Adipose derived mesenchymal stem cells were first identified in 2001 as a 
potential cell source for tissue engineering applications.  Zuk, et al. first characterized the 
cells and noted that the cells were able to undergo differentiation down the mesodermal 
lineages including the adipogenic, osteogenic, myogenic, and chondrogenic lineages.  
Compared to the more widely studied mesenchymal stem cells from bone marrow, 
adipose derived stem cells showed a similar cell marker expression profile staining 
positive for the cell markers CD29, CD44, CD71, CD90, CD105; while negative for 
endothelial cell markers CD34 and CD45 (Zuk, Zhu et al. 2002).  When cultured in 
osteogenic media, ADSCs showed up-regulation of the osteogenic genes Runx-2, 
osteocalcin, and had increased alkaline phosphatase activity compared to cells in control 
 28 
media in standard 2-D culture. Knippenberg later showed that ADSCs cultured in the 
presence of BMP- 2 and BMP- 7 showed greater osteogenic differentiation in terms of 
alkaline phosphatase activity compared to controls in standard 2-D culture (Knippenberg, 
Helder et al. 2006).  Moreover, a major advantage of ADSCs is their relative abundance 
as well as their faster proliferation rate compared to bone marrow MSCs.  This allows for 
more rapid expansion to obtain clinically relevant cell numbers (Cowan, Shi et al. 2004, 
Nakagami, Morishita et al. 2006).  These reports demonstrate that ADSCs have similar 
osteogenic potential to MSCs with the added advantage of being highly abundant, 
compared to other cell sources for bone tissue engineering applications.   
Bone tissue engineering research utilizing adipose derived stem cells has been 
limited with mixed outcomes and mainly focused on non-challenging orthopedic defects 
in animal models e.g. calvarial defects as well as defects in the radius and tibia (Rhee, Ji 
et al. , Cowan, Shi et al. 2004, Niemeyer, Fechner et al. 2010).  Cowan showed that 
juvenile and adult ADSCs harvested from rats led to greater bone formation in a critically 
sized calvarial defect compared to untreated controls.  Further, the deposited tissue had a 
greater radiopacity than uninjured bone suggesting robust mineralization. Niemeyer 
investigated the use of ADSCs in a tibial bone defect model.  When undifferentiated 
ADSCs were implanted, little bone was formed and the ADSCs differentiated down the 
adipogenic lineage as evidenced histologically with the presence of lipid filled vacuoles 
in the defect site (Niemeyer, Fechner et al. 2010).  However, a report in which adipose 
derived stem cells were infected with BMP-2 adenovirus showed complete healing of a 
radial defect in rabbits 12 weeks post-implantation (Wei Hao 2009).  Hicok demonstrated 
human adipose derived stem cells produce osteoid in vivo when seeded onto a 
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hydroxyapatite tri-calcium phosphate scaffold and implanted subcutaneously into 
immune deficient mice (Hicok, Du Laney et al. 2004).  Similarly, Park seeded ADSCs 
onto a poly(lactic)-glycolic acid (PLGA) scaffold and analyzed the regeneration in a tibia 
defect model.  In order to achieve mineralization, the cells had to be cultured on the 
scaffold and differentiated prior to implantation (Park, Zhou et al. 2012).  However pre-
differentiation of ADSCs on the scaffold limits their proliferative capacity, and further 
obfuscates the role the cells play in the regeneration process as it is difficult to assess 
newly formed tissue post implantation. These reports demonstrate a critical criterion for 
the implantation of adipose derive stem cells for bone tissue engineering in that ADSCs 
require a degree of cell differentiation to control the behavior of the cells in vivo.  
While pre-differentiation and gene therapy via viral transfection are widely 
studied techniques for controlling cell behavior, this has several drawbacks in the terms 
of clinical translation.  A pharmacological approach would provide a simpler method to 
promote differentiation along a given lineage.  Reports have shown that resveratrol is 
able to modulate both osteogenesis and adipogenesis.  This appears to be caused by 
stimulating the Sirt1 pathway, which simultaneously promotes osteogenic differentiation 
and inhibits adipogenic differentiation (Backesjo, Li et al. 2006, Costa, Rohden et al. 
2011, Tseng, Hou et al. 2011).  Thus, adipogenesis is down-regulated in the presence of 
resveratrol by inhibition of PPAR-γ, a key player in the control of adipocyte 
differentiation.  Further, Backesjo showed that resveratrol treatment on mouse MSCs 
promoted osteogenic differentiation due to up-regulation of the Sirt1 pathway (Backesjo, 
Li et al. 2006).  The Sirt1 pathway ultimately leads to up-regulation of Runx-2 leading to 
osteogenic differentiation.   
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SUMMARY 
Bone is a highly complex organ responsible for multiple physiologic functions.  
The cellular components of bone give it the ability to regenerate itself in the case of 
fracture.  However, in catastrophic injuries or volumetric tissue loss, the regenerative 
capacity of bone may be insufficient for functional repair.  Current grafting techniques 
such as autograft and allograft have their limitations and challenges.  As such, tissue 
engineering has risen as a possible alternative for the treatment of these defects.  By 
utilizing a scaffold or carrier along with growth factors and/or stem cells, new treatment 
strategies can be developed.  In this thesis, we investigated a cell based tissue engineering 
approach by utilizing adult stem cells, specifically ADSCs and BMMSCs, to generate 
bone tissue in biologically active hydrogels. 
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CHAPTER 3: RESVERATROL AS A PHARMACOLOGICAL 
AGENT TO INCREASE THE OSTEOGNEIC DIFFERENTIATION 
OF ADIPOSE DERIVED STEM CELLS* 
 
ABSTRACT 
The goal of these studies was to investigate the effect of resveratrol treatment on 
the osteogenic potential of human and rat adipose derived stem cells both in a 2-D and 3-
D culture environment.  Adipose derived stem cells (ADSCs) have shown promise as a 
potential source of osteogenic progenitor cells.   Resveratrol has been shown to inhibit 
adipogenic differentiation while simultaneously activating osteogenic differentiation.  2-
D experiments with rat ADSCs identified 25 µM of resveratrol as an effective dose to 
increase the production of osteogenic genes.  The effect of 25 µM resveratrol treatment 
was investigated in a pre-treatment and continuous treatment regimen in 3-D culture and 
demonstrated that pre-treatment was sufficient to increase the mineralized matrix 
production of rat ADSCs.  We next sought to investigate whether this result was also 
observable with human ADSCs and found that the human cells did not respond to 25 μM 
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resveratrol in a positive manner suggesting a species specific difference in resveratrol 
dosage.  Therefore we next investigated multiple doses at or below 25 μM resveratrol for 
both rat and human ADSCs.  We found that doses below 25 μM caused significantly 
more mineralization than 0 (untreated) and 25 μM treated cells in a 3-D culture 
environment.  Furthermore, we observed species differences in the total amount of 
mineralized matrix, as well as the mean mineral density suggesting that the nature of 
mineralization of the extracellular matrix was different between species.  Histological 
examination of the scaffolds showed that the human cell constructs remain highly cellular 
in nature with small pockets of mineralization; while rat cell constructs showed much 
larger and more mature mineralized nodules.  Finally, we investigated concurrent 
treatment of resveratrol and BMP-2 in 2-D and 3-D.   It was demonstrated that short-term 
exposure of BMP-2 had no added benefit in terms of mineralization.  Taken together we 
demonstrate dose dependent differences in the mineralization response of human and rat 
ADSCs to  resveratrol treatment, suggesting that in vitro pre-conditioning of 3D adipose-
derived stem cell constructs may be an effective strategy to promote osteogenic 
differentiation prior to implantation. 
 
INTRODUCTION 
Adipose derived stem cells (ADSCs) were first identified in 2001 as a potential 
cell source for tissue engineering applications.  Zuk, et al. first characterized the cells and 
noted that the cells were able to undergo differentiation down the mesodermal lineages 
including the adipogenic, osteogenic, myogenic, and chondrogenic lineages (Zuk, Zhu et 
al. 2001, Zuk, Zhu et al. 2002).  Compared to the more widely studied mesenchymal stem 
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cells (MSCs) from bone marrow, adipose derived stem cells showed a similar cell marker 
expression profile, staining positive for the cell markers CD29, CD44, CD73, CD90, 
CD105; while negative for endothelial cell markers CD34 and CD45 (Gimble and Guilak 
2003).  When cultured in osteogenic media, ADSCs showed up-regulation of the 
osteogenic genes Cbfα-1 (Runx2), osteocalcin, and had increased alkaline phosphatase 
activity compared to cells in control media in standard 2-D culture (Hattori, Sato et al. 
2004, Schaffler and Buchler 2007).  Knippenberg later showed that ADSCs cultured in 
the presence of bone morphogenetic protein 2 and bone morphogenetic protein 7 showed 
greater osteogenic differentiation in terms of alkaline phosphatase activity compared to 
controls in standard 2-D culture (Knippenberg, Helder et al. 2006).  Moreover, a major 
advantage of ADSCs is their relative abundance as well as their faster proliferation rate 
compared to bone marrow MSCs and this allows for more rapid expansion to obtain 
clinically relevant cell numbers compared to MSCs (Cowan, Shi et al. 2004, Fraser, 
Wulur et al. 2006, Nakagami, Morishita et al. 2006). 
Bone tissue engineering research utilizing adipose derived stem cells has been 
limited with mixed outcomes and mainly focused on orthopedic defects in animal 
models, e.g. calvarial defects as well as defects in the radius and tibia (Niemeyer, Fechner 
et al. 2010, Rhee, Ji et al. 2010).  Cowan showed that implantation of juvenile and adult 
ADSCs harvested from rats led to greater bone formation in a critically sized calvarial 
defect compared to untreated controls (Cowan, Shi et al. 2004).  Niemeyer investigated 
the use of ADSCs in a tibial bone defect model.  When undifferentiated ADSCs were 
implanted, little bone was formed and the ADSCs differentiated along the adipogenic 
lineage as evidenced histologically by the presence of lipid filled vacuoles in the defect 
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site (Niemeyer, Fechner et al. 2010).  However, a recent report in which adipose derived 
stem cells were transduced with a BMP-2 plasmid-containing adenovirus showed 
complete healing of a radial defect in rabbits 12 weeks post-implantation (Wei Hao 
2009). These conflicting reports nevertheless demonstrate a critical criterion for the 
implantation of adipose derive stem cells for bone tissue engineering in that they appear 
to require a degree of cell differentiation to direct the behavior of the cells in vivo.  
While gene therapy via viral transduction is a widely studied technique for 
controlling cell behavior, this has several drawbacks in the terms of clinical translation.  
A pharmacological approach would provide a simpler method to promote differentiation 
along a given lineage.  Reports have shown that resveratrol is able to modulate both 
osteogenesis and adipogenesis (Rayalam, Della-Fera et al. 2011).  This appears to be 
caused by stimulating the Sirt1 pathway, which simultaneously promotes osteogenic 
differentiation and inhibits adipogenic differentiation.  Thus, adipogenesis is down 
regulated in the presence of resveratrol by inhibition of PPAR-γ, a key player in the 
control of both osteogenic and adipogenic differentiation (Shockley, Lazarenko et al. 
2009).  Further, studies have shown that resveratrol treatment of mouse MSCs promoted 
osteogenic differentiation due to up-regulation of the Sirt1 pathway (Boissy, Andersen et 
al. 2005, Backesjo, Li et al. 2006, Costa, Rohden et al. 2011).  These data demonstrate 
that resveratrol is a good candidate to promote osteogenic differentiation while 
simultaneously inhibiting adipogenesis in ADSCs and may therefore promote 
mineralization of ADSCs for bone tissue engineering purposes.   
The goal of these studies was to investigate the effect of resveratrol treatment on 
the osteogenic potential of human and rat adipose derived stem cells both in a 2-D and 3-
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D culture environment.  Dose dependency experiments were performed with rat ADSCs 
to identify therapeutic doses of resveratrol.  We next investigated treatment regimens in 
3-D to determine the length of time need to induce a beneficial effect on osteogenic 
differentiation. We next sought to investigate whether this result was also observable 
with human ADSCs and found species differences in 3-D mineralization.  Therefore we 
next investigated multiple doses at or below 25 μM resveratrol for both rat and human 
ADSCs in the 3-D culture environment.  A histological evaluation of the scaffolds after 
mineralization was performed to investigate differences in the nature of mineral 
deposition in the extra cellular matrix.   We analyzed the surface and chemical makeup of 
mineralized constructs using scanning electron microscopy (SEM), x-ray photoelectron 
spectroscopy (XPS), and thermogravimetric (TGA) analyses.  Finally, we investigated 
concurrent treatment of resveratrol and BMP-2 in 2-D and 3-D for rat ADSCs.   
 
METHODS 
Cell Isolation and Culture 
Rat ADSCs were isolated from inguinal fat pads, which are subcutaneous fat 
depots surrounding the thigh, were harvested from multiple 100-125g male Sprague-
Dawley rats (Harlan, Indianapolis, IN) bilaterally according to a protocol approved by the 
Institutional Animal Care and Use Committee at Georgia Institute of Technology and the 
US Army Medical Research and Materiel Command Animal Care and Use Review 
Office.  Briefly, the tissue was pooled and washed three times in Hank’s balanced saline 
solution (HBSS), and digested in 0.25% trypsin for 30 minutes at 37˚C.  The tissue was 
then cut into smaller pieces and digested in 9125 units of collagenase IA (Sigma, St. 
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Louis, MO) and 75 units of dispase (Gibco, Invitrogen, Carlsbad, CA) for three hours.  
The upper layer of adipocytes was removed, and the cell suspension was filtered through 
a 40µm cell strainer.  The digestion was stopped with MSC growth media (GM) (Lonza, 
Basel, Switzerland), which contains fetal bovine serum, and the cells were collected by 
centrifugation.  The cells were plated at 5,000 cells/cm
2
 in T-75 flasks.  Cultures were 
washed twice with phosphate buffered saline (PBS) and fed with GM at 24 and 48 hours 
after plating.  Cell expansion was performed in which cells were grown to sub-confluence 
and then trypsinized and reseeded for 2 passages prior to being cryo-preserved. 
Human ADSCs were isolated from adipose tissue obtained from an adolescent 
donor at the Children’s Healthcare of Atlanta and cells were isolated and cultured as 
described above.  The procuring and processing of the tissue was performed according to 
Georgia Institute of Technology Institute Review Board protocol H08244. 
Passage 2 rADSCs and hADSCs were thawed and cultured in T75 flasks in GM 
(Lonza).  At 80% confluence the cells were passaged and plated at 5000 cells/cm
2
 in GM.  
Starting the following day, the ADSCs were then treated for 7 days with 0, 6.25, 12.5, 
and 25 µM resveratrol in GM.  Media were changed every 48 hours. 
Measurement of Osteogenic Differentiation Markers 
Twenty-four hours prior to harvest, the media were replaced with fresh medium 
with and without resveratrol.  At harvest the conditioned media were collected, and the 
cells were lysed with 0.05% Triton-X 100, 10 seconds of sonication, and one freeze-thaw 
cycle.  Alkaline phosphatase (ALP) specific activity was measured in cell lysates as the 
release of p-nitrophenol from p-nitrophenylphosphate at pH 10.25.  Protein levels were 
measured with a BCA protein assay kit (Pierce, Rockford, IL).  Osteocalcin (OCN) levels 
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in the conditioned media were measured via the Human Osteocalcin Radioimmunoassay 
kit (Biomedical Technologies, Stoughton, MA).  Osteoprotegerin (OPG) levels in the 
conditioned media were measured via the Osteoprotegerin ELISA (R&D Systems, 
Minneapolis, MN). Osteocalcin and osteoprotegerin assays were each run according to 
manufacturer’s instructions and levels were normalized to DNA levels, quantified by 
fluorescent Picogreen labeling of double stranded DNA in the cell lysate (Invitrogen). 
PCL/Collagen 3-D Scaffold Preparation 
PCL scaffolds were prepared as described previously (Peister, Deutsch et al. 
2009).  Briefly, 100x100x9 mm sheets of medical grade poly ε-caprolactone (PCL, 
Osteopore International, Singapore) with 85% porosity were cut with a 5 mm diameter 
biopsy punch to yield a cylindrical scaffold.  The scaffolds were then briefly treated with 
5M sodium hydroxide to roughen the surface and facilitate cell attachment.  Scaffolds 
were then washed three times with sterile water and sterilized overnight via 70% ethanol 
evaporation.  Sterile PCL scaffolds were washed with excess sterile water three times and 
placed into a custom mold.  Rat tail collagen type I (Trevigen, Gaithersburg, MD) was 
diluted with 0.05% acetic acid to 1.5 mg/mL, neutralized with 1M sodium bicarbonate, 
and aseptically pipetted into the mold to occlude the pores of the scaffold.  The 
scaffold/collagen gel constructs were then placed in a -80°C freezer for 1 hour prior to 
being lyophilized overnight.  Lyophilized scaffolds were placed in a sterile scaffold 
holder and into 24-well low-attachment cell culture plates (Corning, Lowell, MA) and 




Treatment Regimen Effect on rADSC and hADSC Osteogenic Differentiation 
Cryo-preserved cells were thawed and plated for 24 hours.  Cells were then 
trypsinized and plated at a density of 250 cells/cm
2
 and cultured for one week in GM.  
One half of the cultures were treated with 25 µM resveratrol every two days.  Cells were 
harvested, counted, and reconstituted at a density of 3 x 10
4
 cells/μL.  100μL (3 x 10
6
) of 
cells were then carefully pipetted onto the tops of the scaffold/collagen constructs and 
allowed to attach to the surface.  After a 1-hour incubation, GM was added to the culture 
wells so that the cell-scaffold constructs were completely submerged in media.  After 48 
hours media were changed to osteogenic differentiation media consisting of α-MEM 
(Invitrogen) supplemented with 16% FBS (Atlanta Biologics, Lawrenceville, GA), 1% 
penicillin-streptomycin (Invitrogen), 50 μg/mL ascorbic acid 2-phosphate (Sigma), 50 
ng/mL thyroxine (Sigma), 6 mM beta-glycerophosphate (Sigma), and 1 nM 
dexamethasone (Sigma).  Cell/scaffold constructs on the continuous resveratrol treatment 
regimen were given osteogenic differentiation medium supplemented with 25µM 
resveratrol.  Media were changed twice weekly during culture on the 3D scaffolds.  
Scaffolds were placed in a custom holder consisting of a plastic disk with four stainless 
steel pins, and cultured in a 24-well low-attachment cell culture plate.  Cells were 
cultured dynamically on an orbital shaker (Stovall Life Scientific, Greensboro, NC) at a 
rate of 6.5 RPM in a 5 % CO2 incubator.   
Cell Distribution and Seeding Efficiency in 3D Environment 
Cell/scaffold constructs were harvested 24 hours after seeding.  Scaffolds were 
bisected.  A live/dead assay was performed on one half with the LIVE-DEAD 
Viability/Cytotoxicity kit (Invitrogen).  Qualitative distribution of the cells throughout 
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the scaffold was observed via fluorescent microscopy using a Zeiss Axio Observer 
(Gӧttingen, Germany) microscope at 4x magnification.    Non-attached cells were 
collected from the media samples 24 hours after seeding and DNA quantified.  The 
number of cells on the scaffold was determined using the Pico Green DNA assay 
(Invitrogen) together with a standard curve.  Cell numbers were then normalized to the 
number of cells delivered. 
Micro-CT Imaging 
At 4, 8, and 12 weeks, cell scaffold constructs were aseptically removed from 
culture and placed in custom tubes for micro-CT scanning.  Mineralized matrix in the 
cell/scaffold constructs was determined by using a VivaCT scanner (Scanco Medical, 
Brüttisellen, Switzerland) at 55 kVp, 109 mA, 1024 mu scaling, and a 200 ms integration 
time.  The constructs were evaluated with a lower threshold of 80 with a filter width of 
1.2 and a filter support of 1.0.  The total volume of the mineralized matrix as well as the 
mean mineral density of the mineralized nodules was determined.   
Dose Dependent Resveratrol Pre-treatment of rADSCs and hADSCs 
Cryo-preserved cells were thawed and plated for 24 hours.  Cells were then 
trypsinized and plated at a density of 250 cells/cm
2
 and cultured for one week in GM, 
GM supplemented with 6.25 μM resveratrol, 12.5 μM resveratrol, or 25 μM resveratrol.  
Cells were grown for one passage and trypsinized at sub-confluence.  Cells were then 
harvested and seeded onto PCL/collagen scaffolds as described in 2.3 and placed in 
osteogenic media after 48 hours and cultured on an orbital shaker.  Micro-CT imaging 
was performed at 4, 8 and 12 weeks as described previously.  At the end of 12 weeks, 3 
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scaffolds of each group were fixed in 10% neutral buffered formalin for 48 hours and 
then evaluated histologically.  The remaining samples were used for fluorescent imaging. 
Concurrent Resveratrol and BMP-2 Treatment of rADSCs 
Cryo-preserved cells were thawed and plated for 24 hours.  Cells were then 
trypsinized and plated at a density of 250 cells/cm
2
 and cultured for one week in G or 
GM supplemented 12.5 μM resveratrol.  Cells were grown for one passage and 
trypsinized at sub-confluence.  Cells were then harvested and seeded either at 5000 cells/ 
cm
2
 into tissue culture plastic for 2-D culture or onto PCL/collagen scaffolds for 3-D 
culture as described in 2.3 and placed in growth media supplemented with 500 ng of 
BMP-2 for 48 hours.  Media was changed to osteogenic media and continuously cultured 
on an orbital shaker.  2-D samples were analyzed via von Kossa staining, DNA content, 
total calcium content and alkaline phosphatase activity after 14 days.  Micro-CT analysis 
was performed at 4 and 8 weeks as described previously for the 3-D samples, and then 
processed for fluorescent histology as described previously. 
Fluorescent Imaging and Histological Evaluation 
Fluorescent imaging was performed on scaffolds following 24 hours of culture.  
Scaffolds were washed with PBS thrice and then sectioned longitudinally and stained 
with calcein and ethidium and imaged using a Zeiss Axio Observer (Gӧttingen, 
Germany) microscope at 4x magnification.  Fixed samples were sectioned longitudinally 
and von Kossa staining for mineralized matrix was performed.  Gross images of the 




Surface Characterization and SEM Imaging 
The surface morphology of PCL, PCL/Col, PCL/Col-hADSCs, and PCL/Col-
rADSCs was obtained by using a Hitachi S-3700 VP-scanning electron microscope 
(Hitachi high technologies America, Inc., USA) with an accelerating voltage of 15 kV. 
Elemental distribution of the substrates used in this study was analyzed by using the 
energy-dispersive x-ray spectroscopy (EDX) detector attached to the Hitachi S-3700N 
VP-SEM. In order to determine organic and inorganic contents of PCL, PCL/Col, 
PCL/Col-hADSCs, and PCL/Col-rADSCs, thermogravimetric analyses (TGA) were 
performed under nitrogen using a TA Instruments Q50 Thermogravimetric Analyzer 
(Delaware, USA). Substrates weighing approximately 10 – 30 mg were heated from 25 
°C to 800 °C at a rate of 10 °C/minute and the weight loss percentage of each substrate is 
reported. The surface chemical composition and chemical mapping were carried out by 
using x-ray photoelectron spectroscopy (XPS; Thermo K-Alpha, Thermo Fisher 
Scientific Inc., MA, USA). The XPS analysis was performed under ultra-high vacuum 
(less than 10-9 Torr) with a monochromatic Al Kα X-ray source (hv = 1486.6 eV, 90° 
take-off angle). Thermo Advantage 4.43 software package (Thermo Fisher Scientific, 
Inc.) was used to evaluate the XPS spectra.  
Statistical Analysis 
Data were analyzed with a one-way ANOVA followed by a Tukey’s post hoc 
analysis with a significance level of p<0.05.  All groups had 6 independent samples per 





Resveratrol Treatment Effect on Osteogenic Markers for rADSCs in 2-D 
Resveratrol treatment for 7 days had no significant effect on DNA levels (Figure 
3.1A). Alkaline phosphatase specific activity was increased in cells grown in osteogenic 
media (OM) compared to cells cultured in growth media (GM) (Figure 3.1B). Treatment 
with 25 µM resveratrol increased alkaline phosphatase-specific activity in both media. 
Similarly, OCN levels were higher in OM than in GM (Figure 4B). Osteocalcin levels 
were increased by resveratrol in both media, but at the lower concentration of 12.5 µM 
and with no further increase at the higher dose (Figure 3.1C). Osteoprotegerin (OPG) 
levels were reduced in cultures grown in OM compared to GM and resveratrol had no 
effect on this marker (Figure 3.1D). 
Effect of Treatment Regimen on rADSC 3-D Mineralization 
 Both resveratrol treated and untreated cells readily attached to the PCL–collagen 
constructs by 24 hours, as seen on the live/dead images (Figure 3.2A). DNA 
quantification showed that resveratrol treatment had no significant effect on the seeding 
efficiency onto the PCL scaffolds (Figure 3.2B). After 4 weeks of dynamic cell culture in 
osteogenic medium, micro-CT imaging showed that resveratrol treated and untreated 
cells both produced mineralized matrix throughout the entirety of the scaffold (Figure 
3.3A). Resveratrol-pretreated cells produced significantly higher mineralized matrix with 
an average 33% more mineralized matrix than untreated cells at 4 weeks. In addition, 
continuous treatment with resveratrol did not produce a more robust effect on 
mineralization (Figure 3.3B). The pre-treated group showed levels of mineralization  
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Figure 3.1. Effect of resveratrol on osteogenic biochemical markers. ADSCs were 
plated in 24-well plates and treated with 0, 12.5 and 25 M resveratrol in GM and OM. 
After 7 days of treatment, DNA (A), alkaline phosphatase-specific activity (B), OCN 
levels (C), and OPG levels (D) were measured. Data represented are mean ± SEM of 
six independent samples; *p<0.05, Res vs 0mM; #p<0.05, OM vs GM. 
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Figure 3.2. Live/Dead imaging demonstrating rADSC attachment to the scaffold as 
well as a cellular and collage network spanning the struts of the scaffold (A). Similar 
levels of seeding efficiency were seen in untreated and resveratrol treated ADSCs (B). 
Scale bar = 300 µm. 
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similar to that of the continuously treated group, suggesting that a 7 day pre-culture was 
sufficient to obtain the desired effect of early mineralization. After 8 weeks of culture, no 
significant differences in the treatment modalities were observed, although all groups 
continued to mineralize over time. This is most likely due to the amount of 
osteoprogenitors in the untreated cell group having sufficient time to catch up with the 
resveratrol-treated groups, resulting in equal amounts of mineralization. Results at week 
12 were similar to those at week 8, albeit with increased mineralization in all groups from 
week 8 to week 12. 
hADSC Cell Distribution and Seeding Efficiency on PCL/Collagen Scaffolds 
Live/Dead imaging showed high cell attachment and viability for both groups.  
Cells were readily observable attached to the struts of the scaffold as well as forming 
cell/collagen networks that span in between the struts of the scaffold (Figure 3.4).  This 
was confirmed by measuring the seeding efficiency via pico Green DNA assay.  Cells 
that were pre-treated with 25 μM resveratrol had a seeding efficiency of 97.6±.4% while 
untreated cells had a 97.5±.9% of cells seeded. 
Resveratrol Pre-treatment and Continuous Treatment on hADSC Mineralization 
Human ADSCs readily produce mineral on the PCL/collagen scaffolds in the 
presence of osteogenic media as shown in Figure 3.5.  At all time points, resveratrol pre-
treatment (25 μM) resulted in significantly less mineralization than untreated cells.  
Continuous resveratrol treatment (osteogenic media + 25 μM resveratrol) further reduced 
mineralized matrix at all time points.  It should be noted that at each successive time 
point there was a significant increase in mineralized matrix compared to the previous 
time point for each group respectively.   
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Figure 3.3.  Micro-CT reconstructions of rADSC untreated, resveratrol pre-treated, and 
continuously resveratrol treated constructs over time (A).  Quantification of 
mineralized matrix over time (B).  *p<0.05 from untreated group. 
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Figure 3.4. Live/Dead imaging demonstrating hADSC attachment to the scaffold as 
well as a cellular and collage network spanning the struts of the scaffold (A). Similar 
levels of seeding efficiency were seen in untreated and resveratrol treated ADSCs (B). 
Scale bar = 300 µm. 
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Figure 3.5.  Micro-CT reconstructions of hADSC untreated, resveratrol pre-treated, and 
continuously resveratrol treated constructs over time (A).  Quantification of 
mineralized matrix over time (B).  *p<0.05 from untreated group. 
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Dose Dependent Effect of Resveratrol on hADSC and rADSC Osteogenic 
Differentiation 
Micro-CT imaging demonstrated that at 4 weeks all groups of hADSCs were 
mineralizing throughout the entirety of the scaffold (Figure 3.6).  At 4 weeks, the 12.5 
μM group had significantly greater mineral volume than the 25 μM group, indicating that 
a high dose of resveratrol reverses its promotion of mineralization seen in lower dose 
groups (Figure 3.6B).  The 12.5 μM group also approached significance compared to the 
0 μM (untreated) group although it was not statistically significant.  By 8 weeks, all 
groups continued to mineralize with their matrix volume being significantly higher than 
the 4 week time point.  Interestingly, by 8 weeks the 6.25 μM group displayed the 
greatest amount of mineralized matrix and was significantly higher than the 25 μM 
group.  Similar results were observed at 12 weeks, with a significant increase in 
mineralization of all groups compared to the 8 week time point.  These data demonstrate 
that for resveratrol doses lower than 25 μM, pre-treatment of resveratrol is sufficient to 
increase mineralization of human ADSCs with higher doses promoting greater 
mineralization at early time points, and lower doses promoting greater mineralization at 
later time points. 
Mineralization of rat ADSCs was robust in all treatment groups as seen on the 
representative micro-CT images (Figure 3.7).  Quantification of the mineralized matrix 
showed that at 4 weeks the 12.5 μM group significantly increased the mineral volume  
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Figure 3.6.  Micro-CT reconstructions of pre-treated hADSCs at multiple dosages of 
resveratrol (A).  Quantification of mineralized matrix over time (B).  *p<0.05 from 
untreated group except where otherwise noted. 
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Figure 3.7.  Micro-CT reconstructions of pre-treated rADSCs at multiple dosages of 
resveratrol (A).  Quantification of mineralized matrix over time (B).  *p<0.05 from 
untreated group except where otherwise noted. 
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compared to the 0 μM group.  Similar results were observed at 8 weeks with both the 
6.25 μM and 12.5 μM groups having more mineralized matrix than the 0 and 25 μM 
groups.  By 12 weeks the 6.25 μM group was significantly higher than all other dosage 
groups.  At all time points the mineralization increased compared to the previous time 
point for all resveratrol dosages.  It should also be noted that the rat ADSC groups all 
produced more mineralized matrix than the corresponding human ADSC groups at all 
time points. 
hADSC and rADSC Mean Density of Mineralized Matrix 
Quantification of the mean density of the mineralized nodules showed that at 4 
weeks rat and human ADSC constructs showed similar mineral density with only the 25 
µM groups being significantly different (Figure 3.8A).  However at 8 and 12 weeks there 
were significant differences in the mean density with rat cells showing higher mean 
density compared to human cells at all doses (Figure 3.8B and 3.8C).  Interestingly, rat 
ADSC constructs increased in mean density significantly over time for all groups from 4 
to 8 weeks.  From 8 to 12 weeks the middle two doses were significantly different from 
the previous time point although all groups increased in mean density.  At all time points 
human cells had a relatively consistent mean density regardless of resveratrol dose.  
Some groups did significantly increase over time, but the increases were lower than 
observed for the rADSCs.  
Histological Analysis of Mineralized Matrix of hADSC and rADSC Constructs 
Cell scaffold constructs from both species were sectioned longitudinally through 
the middle of the construct and calcein and ethidium imaging of the mineralized matrix 
was performed.  Rat ADSC groups displayed large nodules of mineral with live cells  
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Figure 3.8.  Mean mineral density from micro-CT reconstructions of pre-treated 
rADSC and hADSC constructs at multiple dosages of resveratrol at 4 weeks (A), 8 
weeks (B), and 12 weeks (C).  *p<0.05 species difference at that dose, $ p<0.05 from 
previous time point for that group. 
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Figure 3.9.  Fluorescence imaging of rADSC (A) and hADSCs (B & C) after12 
weeks of culture in osteogenic media (scale bar = .5 mm; green = cells, red = 
mineral).  Von Kossa staining of rADSC (D) and hADSC (E) cell seeded constructs 
after 12 weeks of culture in osteogenic media (scale bar = 1 mm). 
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being found on top of the mineralized nodules as well as on the struts of the scaffold 
(Figure 3.9A).  Human ADSC constructs showed similar results with similar mineralized 
nodules (Figure 3.9B); however there were also large areas of confluent cells that were 
not observed in the rat ADSC constructs (Figure 3.9C).  Von Kossa staining showed that 
both human and rat cell constructs had large deposits of mineral (Figure 3.9D and 3.9E).  
It should be noted that the rat cell groups stained darker and blacker than the human cell 
groups which had a more brownish color, confirming micro-CT results in which the rat 
cell groups had denser mineral nodules than human cell groups. 
Surface Examination of hADSC and rADSC Constructs 
SEM Imaging 
SEM images of the scaffold with and without mineralized cells showed 
distinguishing features. Similar to the fluorescent imaging results, SEM images showed 
that human cell constructs had much more ECM compared to rat cells, however the rat 
cell constructs had much larger nodules compared to the human cells (Figure 3.10C, D, 
G, & H).     
TGA Analysis 
The weight percentage of organic and inorganic contents of substrates used in this 
study was determined by thermogravimetric analysis (TGA). The weight loss profile and 
percentage as a function of increasing temperature from 25 °C to 800 °C is shown in 
Figure 8A. PCL had 99.3% weight loss at 800 °C while PCL with lyophilized collagen 
had 98.8% weight loss. Human and rat cell mineralized constructs had 47%, and 68% 
weight loss, respectively. The weight loss of human bone and rat bone corresponded to  
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Figure 3.10.  Scanning electron microscope images of PCL (A&E), PCL/Col (B&F), 
PCL/Col-hADSCs (C&G), and PCL/Col-rADSCs (D&H). The red dot circle 
indicates the area of higher magnification, shown in the second row of this figure.  
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34% and 33%, respectively. PCL and PCL/Col consist of organic components while 
PCL/Col-hADSCs (mineralized human constructs) and PCL/Col-rADSCs (mineralized 
rat constructs) consisted of both organic and inorganic materials like human and rat 
bones. 
XPS Analysis 
The inorganic contents of PCL/Col-hADSCs and PCL/Col-rADSCs were 
measured by X-ray photoelectron spectroscopy (XPS). Calcium (Ca2p, 347 eV) and 
phosphorous (P2p, 133 eV) peaks were detected in human bone, PCL/Col-hADSCs, rat 
bone, and PCL/Col-rADSCs, however these two peaks were not observed on PCL and 
PCL/Col surfaces (Figure 3.11B) demonstrating that inorganic mineral deposition by 
human and rat cells occurred in the tissue engineered constructs.  
The distribution of Ca and P on human bone, PCL/Col-hADSCs, rat bone, and 
PCL/Col-rADSCs surfaces was obtained by XPS chemical mapping (Figure 3.11C). In 
human bone samples, Ca and P demonstrated stronger and more widespread intensity 
compared to rat bones. PCL/Col-hADSCs distinctly showed that Ca and P were locally 
concentrated rather than evenly spread. On PCL/Col-rADSCs constructs, Ca and P were 
present with strong intensity and relatively well spread.  The XPS mapping showed 
higher intensity suggesting a denser mineralized matrix for the rat cell constructs 
compared to the human cell constructs, confirming the mean mineral density differences 
we obtained from micro-CT. 
 
 58 
Figure 3.11.  A) TGA decomposition profiles of PCL, PCL/Col, human bone, 
PCL/Col-hADSCs, rat bone, and PCL/Col-rADSCs under N2 atmosphere; B) x-ray 
photoelectron spectroscopy (XPS) general survey spectra for PCL, PCL/Col, human 
bone, PCL/Col-hADSCs, rat bone, and PCL/Col-rADSCs (@ = Ca2p peak, * = P2p 
peak); C)XPS chemical mapping of Ca2p and P2p on human and rat bone (B) and 





Concurrent Resveratrol and BMP-2 treatment of rADSCs 
Von Kossa staining of 2-D cultures was similar among all groups, demonstrating 
that all groups did exhibit some mineralization of their extra cellular matrix as shown in 
Figure 3.12.  Quantitative assays were also performed to further examine differences in 
the culture conditions.  BMP-2 significantly reduces the DNA content of the cell cultures 
after 2 weeks in osteogenic media in non-resveratrol treated cells.  There was a 
significant reduction in resveratrol treated cells in terms of DNA content compared to 
non-treated cells Figure 3.12B).  Total calcium content showed a significant increase in 
resveratrol treatment (Figure 3.12C).  Alkaline phosphatase activity indicated that the 
resveratrol and BMP-2 supplemented cultures exhibited significantly higher activity than 
the other groups (Figure 3.12D).   
Our 3-D results indicated a significant increase in mineral volume in resveratrol 
treated ADSCs, consistent with our previous dose dependency and treatment regimen 
studies.  Further, we did not see a significant increase in BMP-2 supplemented cultures in 
either resveratrol treated or non-treated cells, although the means were slightly higher in 
each treatment group respectively.  Qualitatively, we observe that there is mineral 
throughout the entirety of the scaffold.  Continuing the culture through 8 weeks we 
observed very similar results, although there were significantly higher levels of 
mineralization for all groups compared to the 4 week time point. Representative images 
and mineral volumes quantified via micro-CT reconstruction are shown in Figure 3.13. 
Resveratrol had a significant effect on the mineralization of the scaffolds, with no effect 
of BMP-2 being observed in both treated and non-treated cell groups.  Fluorescent 
imaging showed that at the end of culture, there were still live cells present on the  
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Figure 3.12.  Von Kossa staining of concurrent resveratrol and BMP-2 treated 
samples in 2-D cultures (A).  DNA (B), total cellular calcium content (C), and 
alkaline phosphatase activity (D) of 2-D samples after 14 days. * p<0.05 effect of 
resveratrol treatment, $ p<0.05 effect of BMP-2 treatment. 
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Figure 3.13.  Micro-CT analysis of mineralized matrix at 4 and 8 weeks of rADSCs 
concurrently treated with resveratrol and BMP-2.  Quantification of mineralized 
matrix at 4 weeks (A) and 8 weeks (C), and representative reconstructions at 4 weeks 
(B) and 8 weeks (D).  *p<0.05 effect of resveratrol treatment. 
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Figure 3.14.  Fluorescent images of concurrent rADSC treated 3-D constructs after 8 
weeks of culture.  Scale Bar = 300 µm. 
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scaffold, suggesting that the mineralization is cell mediated and not caused by 
precipitation from the media (Figure 3.14). 
  
DISCUSSION 
This work examines the osteogenic potential of both rat and human adipose 
derived stem cells in a 3-D environment as well as the impact of pharmaceutical 
treatment to improve the osteogenic potential of the cell source.  Most studies comparing 
cell sources from different species have focused on mesenchymal stem cells from bone 
marrow aspirates (Woodbury, Schwarz et al. 2000, Javazon, Colter et al. 2001, Ikeuchi, 
Ito et al. 2003, Osyczka, Diefenderfer et al. 2004, Zavan, Giorgi et al. 2007).  Further, 
many studies focus on age related differences by comparing adult cells to fetal cells (De 
Coppi, Callegari et al. 2007, Guldberg, Oest et al. 2007, Peister, Woodruff et al. 2011).  
While age is an important consideration, the species from which the cell source is tested 
in tissue engineering models should also be considered in selecting a cell source.  Such 
studies have been limited to examining different strains of mice (Peister, Mellad et al. 
2004), and to our knowledge only one study has looked at the difference in osteogenic 
potential of adipose derived stem cells from different species (Ni, Zhou et al. 2009). 
We show that there are differences in the osteogenic potential of the cell sources 
as well as dosage effects of resveratrol to improve osteogenic differentiation.  Adipose 
derived stem cells obtained from rats showed greater mineralization at all time points 
compared to human cells.  Further, the mean density of the nodules in rat cell constructs 
was higher than human at later time points suggesting a more mature mineralization in 
the rat cell constructs.  A possible explanation for this is the use of lyophilized rat tail 
 64 
collagen I in our PCL scaffold system.  Rat cells may be able to assimilate the collagen I 
and remodel and mineralize it more efficiently than the human cells.  This is supported by 
the differences seen at the early time point of four weeks as well as the larger mineral 
nodules observed in the rat cell constructs.  Human cell mineralization may be altered in 
the presence of human collagen I and should be tested in the future.  Another possible 
explanation for the observed differences in mineralization may be related to variations in 
resveratrol metabolism.  Human cells and rat cells have been shown to metabolize 
resveratrol differently and this may influence the osteogenic differentiation of the cells 
(Yu, Shin et al. 2002).   
Resveratrol has been shown to induce osteogenesis in preference to adipogenesis 
in mesenchymal and adipose derived stem cells (Backesjo, Li et al. 2006, Erdman, Dosier 
et al. 2011).  Previous work in our lab demonstrated that rat adipose derived stem cells 
pre-treated with resveratrol produce more mineralized matrix than untreated and 
continuously treated cells (Erdman, Dosier et al. 2011).  We extended this work to 
analyze human adipose derived stem cells.  We observed that the human cells did not 
respond well to the 25 μM resveratrol dose regardless of treatment regimen.  We 
therefore performed a dose dependency study evaluating pre-treatment with resveratrol 
for both human and rat adipose derived stem cells.  We observed dosage differences in 
both rat and human cell constructs.  For both rat and human cell constructs, 12.5 μM 
resveratrol pre-treatment resulted in greater mineralized matrix at 4 weeks.  Doses higher 
than 12.5 μM led to decreased mineralized matrix suggesting a potentially cytotoxic 
effect.  At later time points, a lower dose of 6.25 μM resveratrol had the greatest 
mineralized matrix.  Taken together, this suggests that higher doses lead to more rapid 
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differentiation and thus higher mineralized matrix initially, while lower doses promote 
differentiation while retaining better cell viability, resulting in greater mineralized matrix 
at later time points.  These results suggest that the resveratrol dosage should be taken into 
consideration and tailored for the bone tissue engineering application.  For short time 
course studies, a higher dose may produce the best results in terms of mineral production, 
and contrarily for long time course studies a lower dose may be the most beneficial.   
Concurrent treatment of resveratrol and BMP-2 did not result in any added benefit 
in terms of mineralization in vitro.  Others have shown that short exposure times to BMP-
2 are capable of inducing differentiation of ADSCs in vitro (Overman, Farre-Guasch et 
al. 2013).  Our result is most likely due to the relatively short exposure time of BMP-2 
relative to the long-term culture in osteogenic media.  As such, any up-regulation of 
genes by BMP-2 is ameliorated by the 4 week time point.  This agrees with our alkaline 
phosphatase data that demonstrated at 14 days there was an effect of BMP-2 in 2D 
culture. 
The PCL/collagen system used in this study provides a consistent and 
reproducible method to evaluate the osteogenic potential of cells from a variety of 
sources.  Our lab and others have used this to test cells from human bone marrow 
aspirates, amniotic fluid stem cells, mouse cells, and now adipose derived stem cells 
(Guldberg, Oest et al. 2007, Peister, Deutsch et al. 2009, Rai, Lin et al. 2010, Erdman, 
Dosier et al. 2011).   An advantage of this system is the consistent porosity as each 
scaffold is punched from a uniform sheet of material.  This eliminates the variable of 
poor mass transport due to varying porosity in the scaffold affecting the results.  As such, 
any differences observed should be solely attributable to the osteogenic potential of the 
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cell source.  When we mapped the mineral distribution of the mineralized matrix using 
XPS, we observed that the rat cells had higher mineral content compared to human 
constructs.  As expected, when compared to native bone from both rats and humans 
however, the mineral content within the 3-D constructs was markedly lower, indicating a 
still immature mineralized extracellular matrix relative to bone tissue.     
SUMMARY 
In this study we evaluated the osteogenic potential of human and rat adipose 
derived stem cells subjected to pre-treatment with resveratrol prior to seeding within 3-D 
tissue-engineered constructs.  We found that the dose of resveratrol has a significant 
effect on the mineralized matrix production of both cell sources.  We further found that 
rat adipose derived stem cells produce a larger quantity and more mature mineralized 
matrix compared to the human cell constructs.  Taken together we demonstrate that the 
species as well as resveratrol dose can have a significant effect on the mineralized matrix 
production of adipose derived stem cells. 
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CHAPTER 4: EVALUATION OF SYNTHETIC AND NATURALLY 
BASED HYDROGELS AS AN INJECTABLE CELL DELIVERY 
VEHICLE FOR BONE TISSUE ENGINEERING 
 
ABSTRACT 
The goal of these experiments was to evaluate synthetic and naturally based 
hydrogels as a cell delivery vehicle for bone tissue engineering.  Poly-ethylene glycol 
(PEG) and alginate based hydrogels were studied for both in vitro cell viability and in 
vivo ectopic mineralization in a subcutaneous implant model.  We first compared 
traditionally molded 10% w/v PEG hydrogels and injectable PEG hydrogels, as well as 
the incorporation of cell adhesive peptide RGD, for in vitro cell viability at 14 days.  We 
found that the injectable hydrogels with a RGD sequence tethered to the backbone 
resulted in the greatest amount of cell viability.  Therefore, we tested these hydrogels for 
in vivo ectopic mineralization by incorporating 1 million green fluorescent protein 
expressing adipose derived and bone marrow derived mesenchymal stem cells (ADSCs 
and BMMSCs respectively) co-delivered with 2 µg of BMP-2.  Very little ectopic 
mineralization was observed in any of the groups, and the hydrogel remained largely 
intact most likely due to its high weight to volume percentage.  We therefore tested a 
lower weight percentage hydrogel in alginate-based hydrogels.  2% w/v alginate 
hydrogels demonstrated high cell viability over a 14 day time course, and an increase in 
cell number was observed via DNA analysis.  Further, alginate hydrogels were shown to 
be an effective delivery method for in vivo ectopic mineralization, with BMMSC loaded 
hydrogels resulting in greater mineralization than acellular hydrogels.  We therefore 
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conclude that an injectable alginate hydrogel system may be an attractive option as a cell 
delivery vehicle for bone tissue engineering. 
 
INTRODUCTION 
 In the case of volumetric bone loss, such as traumatic injury or in tumor resection, 
the loss of progenitor cells or damage to surrounding tissue can limit the endogenous 
healing capacity of the patient, resulting in nonunion of the defect (Bruder and Fox 
1999).  Presently, the clinical gold standard for treatment of large segmental bone defects 
is autologous bone grafting.  This procedure, however, is severely constrained by a 
limited supply of available graft material, insufficient structural properties and significant 
donor site morbidity (Bauer and Muschler 2000, Nandi, Roy et al. 2010).  An alternative 
treatment is processed bone allografts.  Again, this treatment possesses significant 
limitations, including an unacceptably high rate of post-implantation failure, largely 
attributable to the inability of the graft tissue to fully revascularize and remodel (Wheeler 
and Enneking 2005, Nandi, Roy et al. 2010).  Cell based tissue engineering strategies 
utilizing stem cells have the potential to augment the endogenous healing response 
resulting in restoration of tissue and function.  However, questions remain in effective 
delivery strategies of stem cells to facilitate cell viability and differentiation in vivo. 
 Hydrogels have been studied as cell delivery vehicles for bone tissue engineering.  
A hydrogel is characterized by its high water content contained with insoluble polymers 
that form a cross-linked network to retain a shape.  Hydrogels have many characteristics 
advantageous for cell viability.  First, hydrogels are able to facilitate cell adhesion via 
peptide incorporation.  As stem cells are adherent cells, mimicking of the natural ECM is 
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vital to allow proper functioning of cells.  Lack of adhesive peptides can cause stem cells 
to undergo anoikis leading to cell apoptosis.  Second, many have demonstrated that cell 
delivery also requires growth factor co-delivery to promote differentiation of the 
implanted cells.  Encapsulation of growth factors into hydrogels has shown to be 
effective in inducing new tissue formation (Phelps, Landazuri et al. , Boerckel, 
Kolambkar et al. 2011, Kolambkar, Boerckel et al. 2011, Kolambkar, Dupont et al. 
2011).  In addition, hydrogels are able to serve as a barrier to the initial host 
inflammatory response, yet will permit host cell invasion and vascularization to 
regenerate a functional tissue.  Finally, hydrogels allow for the system to be injectable.  
Extrusion of the hydrogel immediately after cross-linking will lead to generation of larger 
pores other than those inherent to the polymer chain length.  This may ultimately lead to 
greater cell viability by possibly increasing the mass transport within the hydrogel.   
Poly-ethylene glycol (PEG) based hydrogels are an attractive option for bone 
tissue engineering due to their ability to be manipulated to facilitate cellular attachment 
and differentiation.  Cellular attachment and spreading allows for cellular deposition of 
extra cellular matrix molecules, thus leading to the possibility of mineralized matrix 
within the hydrogel.   This has been demonstrated by Burdick in which mineralized 
matrix was found on PEG hydrogels with tethered RGD (Burdick 2002).  Betz 
demonstrated that modification of the PEG hydrogel to generate larger pore sizes resulted 
in increased osteoblastic gene activity and protein production by human mesenchymal 
stem cells (Betz, Yeatts et al. 2010).   These studies suggest that PEG hydrogels may be a 
viable platform as an injectable cell delivery vehicle for bone tissue engineering 
applications. 
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Alginate has been shown to be an effective delivery vehicle for biologics for bone 
tissue engineering.  Kolambkar demonstrated that when paired with BMP-2, alginate 
hydrogels are able to heal critically sized femoral segmental defects in rodents 
(Kolambkar, Boerckel et al. 2011, Kolambkar, Dupont et al. 2011).  Mechanical testing 
showed that the regenerated bone tissue was not significantly different from intact bone 
demonstrating successful functional repair of the defect.   Boerckel followed this study 
with a dose dependency study demonstrating that the dose of BMP-2 affects the amount 
of regenerated tissue in a critically sized segmental bone defect.  Further, it was 
demonstrated that the alginate and BMP-2 system resulted in greater bone formation than 
the clinically used collagen sponge with an equal amount of BMP-2 (Boerckel, 
Kolambkar et al. 2011).  The backbone chain of alginate can be manipulated with cell 
attachment motifs to facilitate cell adhesion and cell differentiation (Rowley and Mooney 
2002, Comisar, Kazmers et al. 2007).  Alsberg demonstrated that RGD functionalized 
alginate hydrogels are able to support in vivo bone formation (Alsberg, Anderson et al. 
2001).  As such, alginate is an attractive platform to test as a potential injectable cell 
based bone tissue engineering delivery vehicle.    
The aim of this study was to evaluate PEG and alginate based hydrogels as cell 
delivery vehicles for bone tissue engineering.  Our hypothesis was that the generation of 
macropores via injection would facilitate greater cell viability in vitro than traditional 
mold cast hydrogels, ultimately leading to greater bone volume in vivo with the 
incorporation of bone morphogenetic protein 2 (BMP-2).  The hypothesis was first tested 
using PEG hydrogels and a histomorphometric analysis of green fluorescent protein 
(GFP) expressing ADSCs and BMMSCs in vitro, quantifying the amount of GFP 
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expressing cells and the amount of dead cells over a 14 day time course.  We next tested 
the PEG system for in vivo mineralization with adult stem cells and BMP-2 co-delivery 
and found limited mineralized tissue due to lack of resorption of the PEG hydrogel.  
Therefore low weight percentage irradiated and oxidized irradiated alginate hydrogels 
were then tested as cell delivery vehicles.  Cell viability was assessed over a 14 day time 
course using a histomorphometric analysis and confirmed via DNA content.  In vivo 
ectopic mineralization was then evaluated with a subcutaneous implant model, with the 
presence of implanted cells assessed after 8 weeks.   
 
METHODS 
Isolation of GFP ADSCs and BMMSCs 
Genetically modified Sprague Dawley rats that express GFP ubiquitously (SD-
Tg(GFP)2BalRrrc) were obtained from the Rat Resource and Research Center (RRRC, 
Columbia, MO).  3 males weighing 120-150 grams were euthanized and their adipose 
tissue and bone marrow harvested as described previously.  Briefly, adipose tissue was 
pooled and washed three times in Hank’s balanced saline solution (HBSS), and digested 
in 0.25% trypsin for 30 minutes at 37˚C.  The tissue was then cut into smaller pieces and 
digested in 9125 units of collagenase IA (Sigma, St. Louis, MO) and 75 units of dispase 
(Gibco, Invitrogen, Carlsbad, CA) for three hours.  The upper layer of adipocytes was 
removed, and the cell suspension was filtered through a 40µm cell strainer.  The 
digestion was stopped with MSC growth media (GM) (Lonza, Basel, Switzerland), which 
contains fetal bovine serum, and the cells were collected by centrifugation.  The cells 
were plated at 5,000 cells/cm
2
 in T-75 flasks.  Cultures were washed twice with 
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phosphate buffered saline (PBS) and fed with GM at 24 and 48 hours after plating and 
allowed to grow to 90% confluence.  The cells were cryopreserved following expansion. 
For bone marrow mesenchymal stem cells, femurs and tibias were harvested 
aseptically.  Both epiphyseal ends were cut and the marrow flushed out in α-MEM into 
tissue culture plates (Gibco, Grand Island, NY).  After 1 hour, the media was collected 
and then re-plated onto new tissue culture plates.  48 hours later the media was aspirated 
off and the adherent cells grown to 90% confluence, with media changes occurring every 
48 hours.  The cells were cryopreserved following expansion. 
PEG Formulation and RGD Incorporation 
 A 3400 molecular weight PEG diacrylate (PEGDA) was the PEG system utilized 
in these studies (Laysan Bio, Arab, AL).  The cell adhesive peptide sequence 
GGGRGDSP, containing the fibronectin cell attachment domain, was tethered to the PEG 
chain (Peptides International, Louisville KY).   Briefly, a 3400 molecular weight PEG 
chain with a succinimydyl valerate reactive group on one end was reacted at 1:1 molar 
ratios with the peptide on a stir plate for 4 hours.  Reacted products were purified by 
dialysis using a 3500 MW dialysis cassette for 24 hours (Thermo Scientific, Waltham, 
MA).  After purification, the solutions were lyophilized for 48 hours to obtain a powder 
and then stored at minus 20°C until needed.   
PCL Nanofiber Mesh Tube Formation 
 PCL nanofiber mesh tubes were produced as described previously (Kolambkar, 
Boerckel et al. 2011).  Poly (ε-caprolactone) (PCL) pellets (Sigma-Aldrich, St. Louis, 
MO) were dissolved in a 90:10 volume ratio of hexafluoro-2-propanol 
(HFP):dimethylformamide (DMF) (Sigma-Aldrich) to obtain a 12% (w/v) polymer 
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solution.  The solution was stirred overnight and until the solution was homogenous.  The 
polymer solution was loaded in a 5 mL syringe (Becton-Dickinson, Franklin Lakes, NJ), 
and a 22 gauge blunt stainless steel needle (Jensen Global Inc., Santa Barbara, CA) was 
attached to the syringe end.  The syringe was mounted on a syringe pump (Harvard 
Apparatus, Holliston, MA) set at a rate of 0.75 mL/hr.  Electrospun fibers were collected 
on foil covering a copper plate (McMaster-Carr, Atlanta, GA) which was placed at a 
distance of 20-23 centimeters from the needle end.  Fibers were electrospun for 5 hours at 
a voltage of 15-20 kV, supplied by a high voltage power supply (Gamma High Voltage 
Research, Ormond Beach, FL). The residual solvent from the meshes was allowed to 
evaporate by placing them in a dessicator until use.  Sheets of electrospun nanofibers 
were cut via laser cutter (Universal Laser Systems, Scottsdale, AZ) into 12mm x 18 mm 
squares, with 1 mm holes perforating the middle of the mesh to allow nutrient transport.  
Meshes were removed from the foil by submerging them in 70% ethanol (VWR, West 
Chester, PA).  The rectangular mesh samples were then wrapped around a stainless steel 
mandrel (McMaster-Carr, Atlanta, GA) to form a tube approximately 5 mm in diameter 
and 12 mm length. The overlapping edges of the mesh were secured via UV glue 
(DYMAX Corporation, Torrington, CT), which was cured with a LED spot curing lamp 
(DYMAX Corporation).  Tubes were then placed in ethanol for overnight evaporation.  
Prior to use, tubes were washed thrice with PBS (Mediatech Inc., Manassas, VA.)   
Molded and Injected PEG Hydrogel Preparation 
 PEGDA and RGD tethered PEG powders were mixed in a 3:1 mass ratio and re-
suspended in PBS.   Re-suspended polymers were mixed in multiple 1 mL syringes with 
1 million cells and/or 2 µg of BMP-2 (R&D Systems, Minneapolis, MN) and a 10% 
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cross-linker consisting of tetramethylethylenediamine (TEMED) and ammonium 
peroxydisulfate (APS).   For molded hydrogels, 150 µL of solution was injected into PCL 
nanofiber tubes placed in custom molds and the hydrogel cross-linked in the mold.  After 
cross-linking, the PCL mesh tubes containing the hydrogel were placed into custom 
holders in a 24-well plate (Corning, Lowell, MA).  Injected hydrogels were allowed to 
cross-link in the syringes and then injected into PCL nanofiber tubes placed in sterile 
custom holders in a 24 well plate.  Samples were cultured for 14 days in α-MEM 
supplemented with 16% fetal bovine serum, and 1% pen-streptomycin L-glutamine with 
media exchanges occurring every 48 hours. 
Alginate Hydrogel Preparation 
 Alginate hydrogels were prepared as described previously (Boerckel, Kolambkar 
et al. 2011).  Sterile irradiated RGD functionalized alginate was obtained from FMC 
Biopolymer (FMC Biopolymer, Philadelphia, PA).  Oxidized-irradiated alginate was 
kindly provided by Ovijit Chaudhuri of Harvard University.  Alginate hydrogels were 
prepared by dissolving the lyophilized polymer in α-MEM to a 3% w/v solution.  The 3% 
w/v solution was then diluted to a 2% solution with either α-MEM or α-MEM containing 
1 million cells.  For BMP-2 containing gels, rat serum albumin (RSA, Sigma Aldrich, St. 
Louis, MO) was dissolved in 4 mM hydrochloric acid to obtain a .1% solution and mixed 
with the lyophilized BMP-2 protein at a 10 µg / 100 µL concentration.  The BMP-2 
solution was added to a syringe at a concentration of 2 µg/150 µL of hydrogel.  Non-
BMP-2 containing hydrogels just received the RSA carrier solution.  Alginate hydrogels 
were then cross-linked with a .21 g/mL calcium sulfate solution and then injected into 
PCL nanofiber mesh tubes placed in a custom holder in a 24 well plate. 
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Cell Viability and Histomorphometric Analysis 
 At times of harvest, hydrogels were taken out of culture and stained for dead cells 
using the ethidium-2-homodimer.  A 1:1000 dilution of the ethidium-2-homodimer was 
prepared in PBS as per manufacturer instructions (Invitrogen, Eugene, Oregon) and the 
hydrogels were placed in 2 mL of solution and agitated gently on a rocker plate for 1 
hour (Stovall Life Scientific, Greensboro, NC).  Hydrogels were then pushed out of the 
PCL nanofiber mesh and placed on a circular cover slip then squeezed with another cover 
slip in a confocal imaging chamber.  For each hydrogel, 3 regions were randomly 
selected and imaged at either 10X or 20 X magnifications on a Zeiss Axio Observer 
(Zeiss, Gӧttingen, Germany) and imaged for GFP positive cells and dead cells.  Cell 
viability was expressed as the percentage of GFP positive cells normalized to the total 
cellular count.   
Alginate Digestion and DNA Quantification 
 Alginate hydrogels in their PCL nanofiber mesh tubes were placed in a 1.5 mL 
Eppendorf tube (Eppendorf, Hamburg, Germany) and immersed in a sodium citrate 
digestion solution.  The tubes were placed in a water bath at 37 degrees Celsius for 5 
minutes.  The PCL mesh tube was then removed, and samples were spun at 15,000 
R.P.M. for 10 minutes.  The digestion solution was then aspirated off leaving a cell pellet, 
and the cells were lysed with 0.05% Triton-X 100, a 10 second sonication, and one 
freeze-thaw cycle.   DNA was measured per manufacturer instruction using the Picogreen 
DNA quantification assay (Invitrogen).  Data was presented as a percentage of the DNA 
levels immediately following hydrogel formation (Day 0 levels).   
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Wet Weight Alginate Degradation Calculation 
 To assess the degradation of irradiated and oxidized-irradiated alginate hydrogels, 
the wet weight of the hydrogel construct was measured at multiple time points.  First, the 
PCL nanofiber mesh and holder were immersed in PBS for 10 minutes and the weight of 
the mesh and holder was determined.  150 µL of alginate hydrogel was then injected into 
the tube and weighed again, giving the day 0 weight and allowing the weight of the gel to 
be determined.   At each take down point, the hydrogel weight was determined and the 
amount of hydrogel lost presented as a percentage of the day 0 weight.   
Subcutaneous Ectopic Mineralization Model 
 Female RNU Nude rats approximately 14 weeks of age underwent a subcutaneous 
implant procedure (Harlan, Tampa, FL).  Aseptic procedures were followed.  Two 2 cm 
incisions were made on the dorsal side of the rat.  Two pockets were made lateral to the 
incision sites by debridement.  Using a stainless steel tube and pole, the hydrogels were 
placed into individual pockets.  Incisions were then closed with a subcutaneous suture 
and wound clips.  All procedures were approved by the Georgia Tech Institute Animal 
Care and Use Committee according to protocol #A10021.   The groups tested for in vivo 
mineralization are listed below. Carrier free was cells in media without hydrogel.  
Micro-CT Imaging for Mineralized Tissue 
Mineralized tissue of the constructs was determined by using a VivaCT scanner 


















iPEG-RGD None No No 
iPEG-RGD + BMP-2 None No Yes 
iPEG-RGD w/ BMMSC BMMSC No No 
iPEG-RGD w/ BMMSC + BMP-2 BMMSC No Yes 
iPEG-RGD w/ ADSC ADSC No No 
iPEG-RGD w/ ADSC + BMP-2 ADSC No Yes 
iPEG-RGD w/ resADSC ADSC 12.5 µM No 






















Acell Yes None No Yes 
ADSC Yes ADSC No Yes 
resADSC Yes ADSC 12.5 µM Yes 
Carrier Free (CF)-resADSC No ADSC 12.5 µM Yes 
BMMSC Yes BMMSC No Yes 
BMMSC w/o BMP-2 Yes BMMSC No No 
Carrier Free (CF)-BMMSC No BMMSC No Yes 
 79 
200 ms integration time.  The constructs were evaluated with a lower threshold of 80 with 
a filter width of 1.2 and a filter support of 1.0.  The total volume of the mineralized 
matrix was determined for each sample. 
Histological Analysis and GFP Cell Immunohistochemistry 
For PEG hydrogels, frozen sections were obtained and stained for mineral via von 
Kossa staining.  Some samples were fixed and saved for GFP immunohistochemistry.  
Histological analysis of alginate hydrogels was performed using paraffin embedding.   
Samples were fixed in 10% neutral buffered formalin (NBF) for 48 hours and then 
decalcified over 2 weeks under mild agitation on a rocker plate. Following paraffin 
processing, 5 μm-thick sections were cut and stained with Haematoxylin and Eosin 
(H&E) and Safranin-O/Fast-green.   
Depariffinized sections were stained for the presence of GFP using a primary GFP 
antibody according to manufacturer instructions (Abcam, Cambridge MA).  Briefly, a 
1:100 solution of primary GFP antibody to PBS was placed on sectioned tissue and 
incubated overnight at 4ºC.  A secondary fluorescently tagged Texas-Red antibody was 
incubated for 1 hour.  Samples were then cover slipped and imaged at 10X magnification 
using the Zeiss Axio Observer.  Sections were also stained for all nuclei using DAPI 
(Invitrogen) to compare to GFP immunostaining to discern between host cells and 
implanted cells. 
Statistical Analysis 
 Data are presented as the mean and standard error.  Data was analyzed via 
ANOVA with a Tukey’s post hoc test for significance.  Significance was determined with 
an alpha level of .05.   
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RESULTS 
Cell Viability in Molded and Injected PEG Hydrogels In vitro 
Cell viability in injected and molded PEG based hydrogels was determined via 
histomorphometry.  Results for the adipose derived stem cells (ADSCs) showed that the 
PEG-RGD containing hydrogel that was injected after cross-linking had the highest cell 
viability and was significantly higher than PEG injectable and the molded PEG (Figure 
4.1).  The injected PEG-RGD has a higher mean than the PEG-RGD mold, though it was 
not significantly different and this was most likely attributable to the limited sample size 
(n=3).  It should also be noted that cell viability in the injected PEG hydrogel was 
significantly higher than the molded PEG hydrogel suggesting that injecting the gel after 
cross-linking provides a greater porosity and increases cell viability.  Further, the data 
also demonstrate that for both injectable and molded gels, the incorporation of RGD has a 
positive effect on cell viability.  This is expected at the 2 week time point as adipose 
derived stem cells are adherent cells and cells undergo anoikis and die without the 
presence of cell attachment peptides. As the images and quantification of GFP positive 
cells show, similar results were observed for both the ADSCs and BMMSCs (Figure 4.2). 
While the trends were near identical compared to the adipose derived stem cells, some 
differences did not reach significance.  Of the differences that were significant however, 
we observed that for molded gels RGD tethering significantly increased cell viability.   
In vivo Ectopic Mineralization in PEG Hydrogels 
 Analysis of mineralized matrix was performed using micro-CT imaging.  Micro-
CT showed small nodules of mineral interspersed throughout the hydrogel volume.  
Quantification of the mineralized matrix showed that BMMSC and ADSC cell seeded 
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Figure 4.1 Representative images of GFP ADSC cell viability after 14 days in 
different PEG hydrogel conditions (A).  Quantification of GFP positive cells 
normalized to total cell count (B).  # p<0.05 from mPEG, $ p<0.05 from iPEG.  
Scale bar = 200 µm.   
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Figure 4.2 Representative images of GFP BMMSC cell viability after 14 days in 
different PEG hydrogel conditions (A).  Quantification of GFP positive cells 




 groups had a greater mean than acellular hydrogels, although the results did not reach 
significance (Figure 4.3).  There was no effect of pre-treating the cells with resveratrol on 
the mineralized matrix production of ADSCs.  In addition, the incorporation of BMP-2 
did not result in an increase in mineral production.  The constructs on the whole largely 
did not mineralize.  We next performed von Kossa staining on frozen sections to confirm 
the presence of mineral.  Positive staining was found primarily where cells were present 
(Figure 4.4).  This demonstrates that the mineralized matrix observed in the micro-CT 
imaging is cell-mediated.  Further, we found cells in the acellular groups, demonstrating 
that there was some host cell invasion into the hydrogel constructs.  We performed 
fluorescent staining with a GFP antibody to determine if the cells observed in the 
hydrogel are implanted cells or the host cells.  While some positive GFP cells were 
present, the majority of the cells in the constructs were negative for GFP suggesting that 
most of the mineralized tissue is from the host cells, as shown in the images below.   
Cell Viability in Alginate Hydrogels 
Cell viability was also assessed in irradiated and oxidized-irradiated alginate 
hydrogels.  We observed that a majority of the cells survive the mixing and injecting 
process of generating the hydrogel (Figure 4.5).  Furthermore, the cell viability 
percentage was in the 80-90% range throughout the 14 day time period for all cell types 
and gel types, demonstrating a much higher percentage of live cells compared to the PEG 
hydrogel system described previously (Figure 4.6).  We also observed that the cells 
appear much smaller at the later time points, hypothesized to be due to proliferation of 
the cells in the hydrogel causing crowding and a smaller phenotype.  This was confirmed 
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Figure 4.3 Representative micro-CT reconstructions of PEG hydrogels (A).  
Quantification of ectopic mineralized matrix (B). 
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Figure 4.4 Representative images of acellular, GFP BMMSC, and GFP ADSC in 
PEG hydrogel following explanation.  Staining for GFP (A-C), DAPI (D-F), and von 
Kossa staining for mineral (G-I).  Scale Bar = 100 µm. 
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Figure 4.5 Representative images of ADSCs, resveratrol treated ADSCs, and 
BMMSCs over a 14 day time course. Scale bar = 100 µm. 
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Figure 4.6 Quantification of live cells in alginate hydrogels at day 1 (A), day 7 (B), 
and day 14 (C).  Analysis of the effect of alginate oxidation over time in terms of cell 
viability (D). * p<0.05 significantly higher than oxidized-irradiated for that cell 
group. 
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Figure 4.7 DNA levels in irradiated alginate hydrogels at day 1 (A), day 7 (B), and 
day 14 (C).  Analysis of the effect of cell type in irradiated alginate over time in 
terms of cell viability (D). * p<0.05 significantly higher than day 1 and day 0 levels, 
$ p<0.05 significantly higher than other cell groups for that time point. 
 89 
with the Picogreen DNA assay, as a significant increase in the DNA content of the 
hydrogel constructs between days 1 and 7 was observed for ADSC, resveratrol treated 
ADSC, and BMMSC cell types (Figure 4.7).  When we pooled the cell groups to assess a 
difference in viability between the irradiated and oxidized-irradiated gel systems we 
observed a significant difference in cell viability with the irradiated hydrogel possessing 
greater viability than the oxidized hydrogel at an early time point.  However at later time 
points there were no significant differences in the viability of the two hydrogel systems. 
Degradation Kinetics of Irradiated and Oxidized-Irradiated Alginate Hydrogels In 
vitro 
As the graphs above show, we observed an initial loss of approximately 20% in 
both the irradiated alginate gels and in the oxidized irradiated gels after only 24 hours in 
culture (Figure 4.8).  This initial loss is most likely due to the loss of hydrogel that was 
not fully cross-linked.  At day 7 we observed no significant differences in terms of mass 
loss between the two different hydrogel systems.  After 14 days, the oxidized irradiated 
hydrogels demonstrated greater mass loss than the irradiated hydrogels.  Further, we 
observed some differences in the cell groups between the irradiated and oxidized gels 
after 14 days in culture, suggesting the cells may be facilitating degradation via 
hydrolysis in the oxidized gels. However, these differences did not achieve significance.    
Subcutaneous Ectopic Mineralization in Alginate Hydrogels 
Micro-CT imaging and processing showed that the adipose derived stem cell 
loaded hydrogels lacked the presence of robust mineralization relative to acellular 
controls (Figure 4.9).  Both resveratrol treated and untreated ADSCs produced less than 2  
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Figure 4.8 Mass loss of both irradiated and oxidized alginate hydrogels over the14 
day time course.  Grouping of the different cell types showed that at day 14 there was 





of mineralized tissue and there was no effect of resveratrol treatment.  The bone 
marrow and acellular groups produced the most ectopic mineralization in vivo as shown 
in the 3-D reconstructions (Figure 4.10).   The acellular group had a mean of 13.7 mm
3 
of 
mineralized tissue.  Interestingly, 3 out of the 6 cellular samples produced robust bone 
formation, while the other 3 did not.  The bone marrow derived stem cell group with 
BMP co-delivery had a mean of 31.8 mm
3 
of mineralized matrix and all 6 samples 
produced robust bone formation.  This group was significantly higher than all other 
groups.  Removal of either the alginate hydrogel carrier or the BMP-2 resulted in a 
significant decrease in ectopic mineralization, demonstrating that the alginate hydrogel, 
BMP-2 and BMMSC cell source are all needed for consistent mineralization. 
Histological Analysis of Harvested Alginate Hydrogels 
Following micro-CT scanning, samples were decalcified and prepared for 
histology.  Histological analysis was performed using H&E and Safranin-O stains, and 
further the presence of implanted cells was tested via immunohistochemistry for GFP 
positive cells.  The presence of cells was observed in acellular constructs demonstrating 
host cell invasion into the hydrogel (Figure 4.11).  ADSC loaded hydrogels had very little 
positive staining for mineralized tissue.  In contrast, there were large areas of 
mineralization observed in BMMSC load hydrogels, consistent with the micro-CT data.  
For carrier free hydrogels, the majority of tissue present was granular and fibrous as there 
was no hydrogel in the construct to impede penetration of host tissue.  GFP positive cells 
were found in cell-loaded constructs with hydrogels, but were not found in acellular 
constructs or constructs lacking hydrogels as expected.  A majority of the cells present  
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Figure 4.9. Representative micro-CT reconstructions of ADSC loaded alginate 
hydrogels and an acellular control (A).  Quantification of mineralized tissue (B).  * 




Figure 4.10. Representative micro-CT reconstructions  of BMMSC loaded alginate 
hydrogels and an acellular control (A).  Quantification of mineralized tissue (B).  * 
p<.05 significantly greater than all other groups, $ p<0.05 significantly less than 
acellular constructs.  
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Figure 4.11. Representative histological section of alginate hydrogels   H&E (A-H), 
Safranin-O (I-P), GFP (Q-X) and DAPI (Y-ff) were performed.  Scale Bar = 100 µm. 
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were not positive for GFP demonstrating that the majority of the cells present in the 
construct after 8 weeks are invading host cells. 
 
DISCUSSION 
This set of experiments sought to investigate PEG and alginate based hydrogels as 
an injectable cell delivery vehicle for bone tissue engineering.  Results demonstrated 
differences in the cell viability and bone formation potential of both materials.  Alginate 
hydrogels had higher cell viability and facilitate greater ectopic mineral formation than 
PEG based hydrogels.  We further demonstrated that implanted cells embedded into the 
hydrogels survive in vivo, and an effect of implanted cells was observed with bone 
marrow mesenchymal stem cells in alginate hydrogels.  Finally, adipose derived stem cell 
loaded hydrogels had significantly less ectopic mineralization relative to acellular 
constructs in the alginate system. 
The limited success of our PEG hydrogels is most likely due to the formulation of 
PEG chosen in this study.  The PEGDA system lacked sites for enzymatic degradation, 
ultimately resulting in limited resorption of the hydrogel once implanted in vivo.  Others 
have had greater success using PEG based materials for bone tissue engineering.  Saito 
used a composite PLA and PEG based material for BMP-2 delivery and noted robust 
mineralization in vivo (Saito, Okada et al. 2001).  However their system incorporated 
enzymatically degradable links that also allowed for controlled release of BMP-2.  A 
study that had non-degrading PEG based hydrogel demonstrated that extremely large 
doses of BMP-2, up to 120 µg, are necessary to achieve bone formation in vivo 
(Murakami, Saito et al. 2002).   Thus, the lack of resorption and low dose of BMP-2 in 
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our PEGDA system likely prevented host cells from reacting with the osteoinductive 
factor, thus limiting the amount of mineralized tissue production, as observed in the 
micro-CT reconstructions.  In addition, the lower cell viability observed in PEG 
hydrogels compared to alginate is likely due to the TEMED and APS cross-linking 
system employed in these experiments.  This system crosslinks the acrylate groups via 
generation of free radicals.  Duan noted significant cell death in the incorporation of 
NIH/3T3 cells in APS and TEMED treated cultures (Duan, Zhu et al. 2005).   Therefore, 
the generation of free radicals likely had a detrimental effect on the cells incorporated 
into the hydrogel thereby leading to lower viability at 14 days.  
When applied to bone defect models, the presence of irradiated alginate is still 
detectable at 12 weeks (Boerckel, Kolambkar et al. 2011).  The presence of alginate 
might have an inhibitory effect on the bone mechanics if it is unable to be remodeled by 
the host cells.  We therefore examined partially oxidized irradiated alginate to determine 
differences in cell viability and degradation rates compared to irradiated alginate alone.  
Others have shown that oxidation of the alginate backbone increases its degradation in 
vitro  (Bouhadir, Lee et al. 2008).  In both the ADSCs and BMMSC groups, we observed 
a significant difference in cell viability 24 hours after encapsulation between the 
irradiated and oxidized-irradiated hydrogels.  When forming the gels, the α-MEM that 
served as the dissolving agent of the oxidized alginate displayed a yellowish hue once the 
alginate was completely dissolved, indicative of a slightly acidic environment.  This 
acidity may have had a detrimental effect on the cell viability at early time points, and 
attribute to why no differences were observed between irradiated and oxidized-irradiated 
hydrogels at later time points.  The degradation kinetics of the irradiated and oxidized-
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irradiated alginate hydrogels was relatively similar over the 14 day time course.  The 
cells incorporated into the alginate hydrogels were in growth media and given no 
differentiation signals.  As such, the cells had no incentive to remodel their environment 
which may account for the limited differences in the degradation of the hydrogels.   
The difference between the results in the adipose and bone marrow mesenchymal 
stem cells for in vivo bone formation is most likely attributable to two factors: 1) cytokine 
signaling to host cells, and 2) time for host cell invasion.  Histological analysis of our 
samples demonstrated a large host cell invasion into the hydrogels.  In the case of adipose 
derived stem cells, we hypothesize that cellular waste products are likely degrading the 
BMP-2 present in the hydrogel preventing host cells from seeing the osteoinductive 
factor.  Further, the BMP-2 dose chosen in this study may have been too low to induce 
robust cytokine activity from the ADSCs. Dudas was able to see an effect of adipose 
derived stem cells treated with BMP-2 at a higher dose on a gel foam scaffold in a 
calvarial defect (Dudas, Marra et al. 2006).  Others have shown that additional factors 
besides BMP-2 are necessary to induce osteogenic differentiation of ADSCs 
(Knippenberg, Helder et al. 2006).  As such, in our current system the ADSCs are likely 
having two detrimental effects on bone formation: too low of an osteoinductive factor 
signaling to stimulate endogenous host cells, and degradation of the delivered growth 
factor preventing endogenous cell mediated bone formation as seen in acellular 
hydrogels.  We believe the reverse case is true for the bone marrow mesenchymal stem 
cells.  For BMMSCs, we believe the BMP-2 is causing an up-regulation of osteoinductive 
factor signaling, which is why these constructs produce consistent robust mineralization 
compared to acellular constructs.  Early time point studies examining the gene and 
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protein production of ADSCs and BMMSCs in these systems are needed to evaluate 
these hypotheses. 
SUMMARY 
 In this study we examined the ability of both natural and synthetic hydrogels to 
support viability in vitro and ectopic mineralization in vivo.  Results showed that 
extruding the hydrogel via injection in the PEG hydrogel system resulted in greater cell 
viability than molded hydrogels.  In addition, there was an added benefit of incorporating 
the RGD cell attachment peptide sequence into the PEG hydrogel.  However, when 
applied to an ectopic subcutaneous mineralization model, little mineralization was 
observed.  There was a large amount of hydrogel still present within the nanofiber mesh 
tube, inhibiting tissue ingrowth.  Conversely, alginate hydrogels demonstrated greater 
cell viability in vitro and supported ectopic mineralization in vivo.  Few differences were 
found in cell viability in irradiated and oxidized-irradiated alginate hydrogels, and 
degradation kinetics were largely similar over a 14 day time course.  Irradiated hydrogels 
were tested for as an injectable cell delivery vehicle for ectopic mineralization.  Results 
showed that co-delivery of BMP-2 and BMMSCs generates robust deposits of 
mineralized tissue consistently.  Adipose derived stem cell loaded hydrogels lacked 
robust mineralized tissue relative to acellular controls.  Further, despite the effectiveness 
of resveratrol in increasing the osteogenic mineralization of ADSCs in vitro, pre-
treatment resulted in no added benefit in vivo.  Taken together, these results suggest that 
incorporation of BMMSCs and BMP-2 into an irradiated alginate based hydrogel will be 
an effective therapeutic intervention for a cell based tissue engineering approach in a 
non-healing bone defect model. 
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CHAPTER 5: EFFECT OF DELIVERY TIME ON THE 
REGENERATION OF BONE IN A NON-HEALING SEGMENTAL 
BONE DEFECT  
 
ABSTRACT 
The healing of critically sized diaphyseal defects remains a clinical problem.  A 
stem cell based approach is an attractive option for current treatment techniques.  In this 
set of studies, we sought to examine the ability of stem cells to heal a critically sized 
defect in the femur of the rat using an alginate based hydrogel as an injectable carrier for 
bone marrow mesenchymal stem cells (BMMSCs).  We further investigated whether 
delaying the time of implantation altered the healing response.  Potential delayed delivery 
time points were determined by examining tissue infiltration into empty defects over a 14 
day time course.  We next attempted to deliver our therapeutic using a blind percutaneous 
technique into the defect site at 14 days without reopening and reinjuring the tissue 
surrounding the defect site.  Inaccurate delivery resulted in unhealed defects, with the 
hydrogel mineralizing in surrounding tissues.  It was further observed that at 14 days 
there is too much infiltrated tissue to deliver the hydrogel.  We therefore altered our 
technique with a second procedure at 7 days and injected the hydrogel with as little 
damage to surrounding tissues as possible.  Quantification of mineralized tissue 
demonstrated that delaying the injection of the hydrogel for 7 days resulted in less bone 
formation than immediate delivery of the hydrogel, however BMMSC incorporation 
resulted in greater bone formation than acellular constructs for both the immediate and 
delayed treatment groups by 12 weeks.  We therefore conclude that immediate delivery 
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of alginate hydrogels with BMMSCs is an effective strategy for the treatment of large 
bone defects.   
 
INTRODUCTION 
In the case of volumetric bone loss, such as traumatic injury or in tumor resection, 
loss of progenitor cells or damage to surrounding tissue can limit the endogenous healing 
capacity of the patient, resulting in nonunion of the defect (Bruder and Fox 1999).  There 
is a large clinical need for effective treatment of such defects.  According to the United 
States Bone and Joint Decade, musculoskeletal conditions are the most commonly 
reported health conditions in U.S. citizens, occurring in roughly 48% of the population.  
Beyond the associated physical afflictions is the enormous financial burden - $849 billion 
in 2004 alone (Decade 2009).  Bone grafting procedures have an annual incident 
occurrence greater than 500,000, resulting in a cost greater than $2.5 billion in the United 
States alone (Laurencin, Khan et al. 2006).    
Current clinical treatment modalities for management of large bone defects are 
limited and often ineffective.  The clinical gold standard for treatment of large segmental 
bone defects is autologous bone grafting.  This procedure, however, is severely 
constrained by a limited supply of available graft material, insufficient structural 
properties, and significant donor site morbidity.  Another often-employed treatment is 
allograft tissue obtained from cadavers.  Again, this treatment possesses significant 
limitations, including an unacceptably high rate of post-implantation failure.  This is 
largely attributable to an inability of the graft tissue to fully revascularize and remodel 
leading to decreased integration of the graft to the host tissue.  There are also additional 
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concerns with regard to disease transmission and immune rejection with allograft use 
(Nandi, Roy et al. 2010).  The occurrence of refracture varies depending on the size of 
the graft, but has been reported to be as high as 25-35%  (Sorger, Hornicek et al. 2001).  
As such, alternative treatment strategies are warranted to address the shortcomings of 
current treatment modalities. 
A new grafting approach has emerged in the clinical treatment of large bone 
defects: the Masquelet technique.  In this procedure, a multi-step operation is undertaken 
to heal a diaphyseal defect.  The first procedure consists of debridement of the bone and 
surrounding soft tissue, and the placement of a large cement spacer in the area of a bone 
defect (Nauth, McKee et al. 2011).  The spacer serves two functions: first, the spacer 
prevents fibrous tissue invasion into the defect site, and second, the foreign body 
response induced by the spacer will form a membrane surrounding the defect site 
(Giannoudis, Faour et al. 2011).   The defect is fixed with an external stabilizer and the 
surrounding soft tissues are allowed to heal.  In the second procedure, the spacer is 
removed with as little disruption of the newly formed membrane as possible, and 
trabecular bone chips are placed in the defect site to allow healing.  This technique has 
been shown to be effective both in animal models and in clinical practice for tibia and 
femur defects (Klaue, Knothe et al. 2009, Stafford and Norris 2010).  The membrane 
surrounding the spacer has been shown to be well vascularized and expresses angiogenic 
and osteogenic factors, including BMP-2, thereby inducing bone formation in the defect 
site (Pelissier, Masquelet et al. 2004).  
While the Masquelet technique has been shown to be effective in the treatment of 
long bone defects, it is still dependent on the harvesting of autologous or allograft tissue.  
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Utilizing stem cells and osteoinductive growth factors in a tissue engineering approach 
for bone regeneration may alleviate the need for grafting substrates.  Previous studies in 
our lab have demonstrated that injectable alginate based hydrogels are in effective 
strategy for growth factor delivery in the treatment of critically sized diaphyseal defects 
in a guided bone regeneration technique (Boerckel, Kolambkar et al. 2011, Kolambkar, 
Boerckel et al. 2011).  However, we have not investigated incorporating stem cells into 
the alginate hydrogel delivery system, nor have we assessed timing of delivery of the 
alginate hydrogel to the defect site.   
The purpose of this study was to investigate the use of an injectable alginate 
hydrogel system loaded with bone marrow mesenchymal stem cells to heal a critically 
sized diaphyseal defect in the femur of the rat.   We hypothesized that delaying the 
delivery of stem cells to the defect site would lead to greater bone regeneration.  Tissue 
infiltration between the creation of the defect and the delivery of the hydrogel would 
allow for greater nutrient exchange and a possible increase in the recruitment of 
endogenous osteoprogenitors to the defect site.  Potential delayed delivery time points 
were determined by examining tissue infiltration into empty defects over a 14 day time 
course.  We next attempted to deliver our therapeutic using a blind percutaneous 
technique into the defect site at 14 days without reopening and reinjuring the tissue 
surrounding the defect site.  Inaccurate delivery resulted in unhealed defects, with the 
hydrogel mineralizing in surrounding tissues.  We therefore employed a two-step surgery 
technique, similar to the Masquelet technique previously described albeit without a 
spacer in the defect site.   The second procedure at 7 days involved injecting the hydrogel 
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with as little damage to surrounding tissues as possible.  All studies used a non-healing 
dose of BMP-2 to assess the influence of cells in the repair process. 
METHODS 
GFP BMMSC Isolation 
Genetically modified Sprague Dawley rats that express GFP ubiquitously (SD-
Tg(GFP)2BalRrrc) were obtained from the Rat Resource and Research Center (RRRC, 
Columbia, MO).  3 males weighing 120-150 grams were euthanized and bone marrow 
harvested as described previously.  Femurs and tibias were harvested aseptically.  The 
epiphyseal ends were cut on both ends and the marrow flushed out in α-MEM into tissue 
culture plates.  After 1 hour, the media was collected and then re-plated onto new tissue 
culture plates.  48 hours later the media was aspirated off and the adherent cells grown to 
90% confluence, with media changes occurring every 48 hours.  The cells were 
cryopreserved following expansion. 
Alginate Hydrogel Formation 
Alginate hydrogels were prepared as described previously (Boerckel, Kolambkar 
et al. 2011).  Sterile irradiated RGD functionalized alginate was obtained from FMC 
Biopolymer (FMC Biopolymer, Philadelphia, PA).  Alginate hydrogels were prepared by 
dissolving the lyophilized powder in α-MEM to a 3% w/v solution.  The 3% w/v solution 
was then diluted to a 2% solution with either α-MEM or α-MEM containing 1 million 
cells.  For BMP-2 containing gels, rat serum albumin (RSA, Sigma Aldrich, St. Louis, 
MO) was dissolved in 4 mM hydrochloric acid to obtain a .1% solution and mixed with 
the lyophilized BMP-2 protein.  The BMP-2 solution was added to a syringe at a 
concentration of 1 µg/150 µL of hydrogel.  Non-BMP-2 containing hydrogels just 
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received the RSA carrier solution.  All solutions were sterilely mixed in 1 mL syringes 
with Luer-Lok connectors (Cole-Palmer, Vernon Hill, IL).  Alginate hydrogels were 
prepared immediately prior to the surgical procedure. 
PCL Nanofiber Mesh Tube Formation 
PCL nanofiber mesh tubes were developed as described previously (Kolambkar, 
Boerckel et al. 2011).  Poly (ε-caprolactone) (PCL) pellets (Sigma-Aldrich, St. Louis, 
MO) were dissolved in a 90:10 volume ratio of hexafluoro-2-propanol 
(HFP):dimethylformamide (DMF) (Sigma-Aldrich) to obtain a 12% (w/v) polymer 
solution.  The solution was stirred overnight and until the solution was homogenous.  The 
polymer solution was loaded in a 5 mL syringe (Becton-Dickinson, Franklin Lakes, NJ), 
and a 22 gauge blunt stainless steel needle (Jensen Global Inc., Santa Barbara, CA) was 
attached to the syringe end.  The syringe was mounted on a syringe pump (Harvard 
Apparatus, Holliston, MA) set at a rate of 0.75 mL/hr.  Electrospun fibers were collected 
on foil covering a copper plate (McMaster-Carr, Atlanta, GA) which was placed at a 
distance of 20-23 centimeters from the needle end.  Fibers were electrospun for 5 hours at 
a voltage of 15-20 kV, supplied by a high voltage power supply (Gamma High Voltage 
Research, Ormond Beach, FL). The residual solvent from the meshes was allowed to 
evaporate by placing them in a dessicator until use.  Sheets of electrospun nanofibers 
were cut via laser cutter (Universal Laser Systems, Scottsdale, AZ) into 12mm x 18 mm 
squares, with 1 mm holes perforating the middle of the mesh to allow nutrient transport.  
Meshes were removed from the foil by submerging them in 70% ethanol (VWR, West 
Chester, PA).  The rectangular mesh samples were then wrapped around a stainless steel 
mandrel (McMaster-Carr, Atlanta, GA) to form a tube approximately 5 mm in diameter 
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and 12 mm length. The overlapping edges of the mesh were secured via UV glue 
(DYMAX Corporation, Torrington, CT), which was cured with a LED spot curing lamp 
(DYMAX Corporation).  Tubes were then placed in ethanol for overnight evaporation.  
Prior to use, tubes were washed thrice with PBS (Mediatech Inc., Manassas, VA.)   
Surgical Procedures 
 Female RNU Nude Rats (Harlan, Tampa, FL) aged 14 weeks underwent a 
bilateral segmental defect procedure as described previously (Oest, Dupont et al. 2007, 
Kolambkar, Boerckel et al. 2011).  Briefly, diaphyseal defects were performed in the 
femur.  Defects were stabilized with a polysulfone internal fixation plate modified with 
two holes in the center to allow for injection into the defect site (Appendix C).  Following 
attachment of the fixation plate, an 8 mm segment of bone was removed from the 
diaphysis.  A PCL nanofiber mesh tube was then placed in the defect site.  For the empty 
defect and delayed defect groups, the defect site was left unfilled with the surrounding 
muscle sutured and the skin closed with wound clips.  Groups receiving immediate 
treatment had a hydrogel implanted into the defect site, followed by closure.   
 For percutaneous delivery, following closure of the skin the internal fixation plate 
was palpated and the center holes of the plate were found by probing with a needle.  The 
syringe containing the appropriate hydrogel was then guided through the hole and 150 µL 
of hydrogel was delivered to the defect site.  The same procedure was followed for 
delayed implantation animals at 14 days prior to removal of the wound clips from the 
initial surgery. 
 For animals receiving two procedures, the animal was reopened 7 days post 















Table 5.1.  Groups for Percutaneous Delivery of Hydrogel 
 
Group Hydrogel Cells BMP-2 Implantation Day 
BMP + Cells RGD Alginate 1e6 GFP BMMSC 1.0 µg 0, 14 Days 
BMP RGD Alginate None 1.0 µg 0, 14 Days 


















Table 5.2.  Groups for 2
nd
 Procedure Delivery of Hydrogel 
Group Hydrogel Cells BMP-2 Implantation Day 
No BMP RGD Alginate None None 0, 7 Days 
BMP RGD Alginate None 1.0 µg 0, 7 Days 
BMP + Cells RGD Alginate 1e6 GFP BMMSC 1.0 µg 0, 7 Days 
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Scabbed tissue was cut away from the initial incision using a scalpel, and the initial 
incision was reopened.  The medial sutures in the surround muscle were cut, and the 
syringe containing the appropriate hydrogel was then guided through the center holes of 
the fixation plate and 150 µL of hydrogel was delivered inside the nanofiber mesh.  The 
muscle was then re-sutured around the fixation plate, and the skin closed via wound clips.   
Faxitron Radiograph Imaging 
Digital radiographs (Faxitron MX-20 Digital; Faxitron X-ray Corp., Wheeling, IL) 
were performed at an exposure time of 11 s and a voltage of 25 kV with the animals under 
anesthesia.  Animals were imaged at weeks 2, 4, and 8 and 12 post defect creation. 
Micro-CT Imaging 
Live animal in vivo micro-CT scans (VivaCT 40, Scanco Medical, Basserdorf, 
Switzerland) were performed with a 38.0 micron voxel size at a voltage of 55 kVp and a 
current of 109 μA.  Analysis of newly formed bone was done with a lower threshold of 
125, corresponding to approximately half the threshold of native cortical bone.  The scans 
were segmented such that only bone inside the nanofiber mesh was included in the 
analysis.  Scans were performed at 4, 8 and 12 weeks post defect creation. 
Ex-vivo scans of harvested femurs were performed at a 21 micron resolution.  To 
assess bone remodeling on the ends of the defect site in empty defects over a 14 day time 
course, samples were scanned and the first 25 slices adjacent to the defect site were 
segmented for trabecular bone in the medullary cavity.   
Histological Analysis 
 Samples were decalcified in Immunocal (Decal Chemcial Corporation, Tallman, NY) 
and prepared for paraffin processing.  Histological analysis was performed using H&E 
staining for general morphology, and Safranin-O for mineralized tissues. 
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Immunohistochemistry was performed for pan macrophage presence in decalcified empty 
defects via CD68 staining according to the manufacturer protocol (AbD Serotec, Bio-Rad, 
Raleigh, NC).  Depariffinized sections were stained for the presence of GFP using a 
primary GFP antibody according to manufacturer instructions (Abcam, Cambridge MA).  
Briefly, our immunohistochemistry procedure was as follows: a 1:100 solution of primary 
antibody to PBS was placed on sectioned tissue and incubated overnight at 4 degrees 
Celsius.  A secondary fluorescently tagged Texas-Red antibody was incubated for 1 hour.  
Samples were then cover slipped and imaged at 10X magnification using the Zeiss Axio 
Observer.  Sections were also stained for nuclei using DAPI (Invitrogen) to discern 
antibody tagged cells from implanted cells. 
Statistical Analysis 
Data are presented as the mean and standard error.  Data was analyzed via 
ANOVA with a Tukey’s post hoc test for significance.  Significance was determined with 
an alpha level of .05. 
 
RESULTS 
Empty Defect Characterization 
An 8 millimeter segmental defect was created in the femur and a poly-
caprolactone nanofiber mesh was implanted into the defect site.  After the mesh was 
implanted, the muscle and skin were sutured and closed leaving the defect site empty.   
At days 3, 7 and 14 femurs were harvested and examined for tissue infiltration into the 
defect site.  Micro-CT imaging showed that little bone formation occurred in the defect 
site over the 14 day time course (Figure 5.1A).    Analysis of the cancellous bone in the 
medullary cavity demonstrated that on the proximal side of the defect there was bone  
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Figure 5.1 Micro-CT reconstructions of empty segmental defects over a 14 day time 
course (A). Quantification of cancellous bone volume fraction in the medullary 
cavity in the bone ends adjacent to the defect site (B). * p<0.05.  
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remodeling causing a significant decrease in the cancellous bone volume fraction over 
time (Figure 5.1B).  Conversely, on the distal side there was a significant increase in the 
cancellous bone in the medullary cavity (Figure 5.1C).  It should be noted that both sides 
approached similar bone volume fractions by day 14, and demonstrates bone remodeling 
occurs quickly after the creation of the defect.    
Histological analysis showed that over the 14 day time course there is a gradual 
filling of the defect site with granular tissue.  At day 3 the defect site is still largely empty 
and there are few macrophages present in the defect site (Figure 5.2).  
Polymorphonuclear cells, indicative of neutrophils, were observed in the defect site and 
at the bone ends.   By day 7 there is more tissue present in the defect site.  
Immunohistochemistry for macrophages showed a large presence of CD68 positive cells 
in the defect site demonstrating macrophage infiltration (Figure 5.3).  A large 
polymorphonuclear cell presence was also observed via H&E staining.  By day 14, the 
defect site is nearly filled with host tissue (Figure 5.4).  On the bone ends, the tissue had 
an organized structure which may be indicative of the beginning of ‘end capping’, where 
the periosteum bridges the cortices adjacent to the defect site in critically sized defects 
that do not achieve union.  There was also a large presence of macrophages and 
polymorphonuclear cells present in the defect site at this time.  The presence of host 
tissue suggested that the implanted cells would be able to achieve nutrient exchange 
facilitating their survival.  Further, as one of the goals of this work is to determine if a 
carrier is needed for cell delivery at a delayed time point, the 14 day time point possibly 
allows for implanted cells to graft into the infiltrated host tissue.  We therefore chose 14 
days as our delayed implantation time point.  
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Figure 5.2 Histological analysis of 8 millimeter empty defects 3 days post defect 
creation.  H&E Stain and immunohistochemistry for CD68. Scale Bar =100 µm. 
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Figure 5.3 Histological analysis of 8 millimeter empty defects 7 days post defect 
creation.  H&E Stain and immunohistochemistry for CD68.  
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Figure 5.4 Histological analysis of 8 millimeter empty defects 14 days post defect 
creation.  H&E Stain and immunohistochemistry for CD68.  
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Percutaneous Delivery of Hydrogels to Segmental Bone Defect 
With the identification of a delayed time point of 14 days, we performed a study 
to investigate the difference between immediate delivery and delayed delivery of the 
therapeutics.  Groups tested were: 1) Alginate hydrogels loaded with 1 million GFP 
BMMSCs and 1 µg of BMP-2, 2) cell free alginate hydrogels containing 1 µg of BMP-2, 
and 3) carrier free constructs consisting of cells in α-MEM and 1 µg of BMP-2.  All 
constructs were delivered percutaneously with the immediate injection occurring after the 
animal had been sutured and stapled following the segmental defect surgery.   The 
delayed time point injections occurred just prior to wound clip removal from the initial 
surgery.   
The results show that the percutaneous delivery of the hydrogel through the skin 
is highly variable in terms of location of the hydrogel.  Particularly for the immediate 
time point, many of the hydrogels were delivered past the defect site and into the 
surrounding tissue (Figures 5.5, 5.6, 5.7).  Despite the inaccuracy of the delivery of 
therapeutics, some observations about the effectiveness of the therapeutics at the two 
different time points can be obtained.  For the immediate injection, all 5 of the cell loaded 
alginate hydrogels mineralized with 4 mineralizing ectopically in the surrounding muscle 
and the 1 sample delivered accurately mineralizing in the defect site (Figure 5.5).  For 
cell free hydrogels, 3 out of 5 produced mineral all of which were ectopically in the 
surrounding muscle (Figure 5.6).  This rate of mineralization for these two groups agrees 
with what was observed in the subcutaneous model for the groups respectively as 
discussed in Chapter 4.  For the carrier free, none of the samples mineralized ectopically 
or in the defect site.  For one sample mineralization along the mesh was observed (Figure  
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Figure 5.5 Radiograph and Micro-CT reconstruction of percutaneously delivered 
hydrogel containing BMP-2 and BMMSCs.  Top row shows a hydrogel delivered to 
the defect site.  Bottom row shows a representative ectopic mineralization sample 
due to inaccurate delivery.  
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Figure 5.6 Radiograph and Micro-CT reconstruction of percutaneously delivered 
hydrogel containing BMP-2.  A representative ectopic mineralization sample due to 
inaccurate delivery is shown in the top row. Bottom row is a representative of a 
sample with little bone formation observed anywhere in the limb. 
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Figure 5.7 Radiograph and Micro-CT reconstruction of percutaneously delivered 
solution of cells and BMP-2.  The top row shows a mesh with significant 
mineralization, possibly due to cell attachment to the mesh. Bottom row is a 
representative of a sample with little bone formation observed anywhere in the limb. 
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5.7). The lack of mineralization is most likely attributable to ambulation of the limb 
resulting in dispersion of the therapeutic since there is no hydrogel to retain the cells and 
BMP-2 at the injection site.   
With more experience in delivering the hydrogels percutaneously, the delayed 
delivery hydrogels were delivered closer to the defect site.   However in some samples 
part of the hydrogel ended up outside the nanofiber mesh.  Results demonstrate that for 
the acellular constructs the mineralization response appears to be less than what was 
observed with 1 µg of BMP-2 in previous studies in our lab (Boerckel, Kolambkar et al. 
2011).  This is possibly due to failure of delivery of the entire 150 µL to the defect site 
and also the presence of host tissue retarding the ability of the hydrogel and BMP-2 to 
form a continuous volume of bone.  For cell-loaded constructs, there appears to be a 
similar amount of bone formation compared to the acellular constructs, with the issues 
just described previously also possibly confounding the results (Figure 5.8).  For the 
carrier free group, there appears to be little bone formation in any samples.  Like the 
immediate injection results for this group, ambulation of the limb may be resulting in 
dispersion of the therapeutic following injection.  Due to the variability of the hydrogel 
delivery location in these experiments, the mineral production was not quantified as it is 
impossible to ascertain whether any difference would be due to the therapeutic 
intervention or the volume actually delivered to the defect site. 
Immediate versus Delayed Bone Formation with 2
nd
 Procedure 
Accuracy of delivery prevented quantification of differences in the groups tested, 
however we were able to discern that the group lacking hydrogel is ineffective for bone  
 120 
Figure 5.8 Radiograph and Micro-CT reconstruction of percutaneously delivered 
constructs 14 days after creation of the defect for the different constructs tested.   
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formation, as well as the 14 day time point being too late to deliver 150 µL of hydrogel 
into the defect site.  Therefore, we altered the surgical procedure to allow for the defect 
site to be visible to ensure accurate delivery, and moved up our delayed time point further 
to 7 days.  The groups tested in this new procedure were: an alginate hydrogel lacking 
BMP-2 or BMMSC incorporation (No BMP), an alginate hydrogel with BMP-2 (BMP), 
and an alginate hydrogel with BMP-2 and 1 million BMMSCs (BMP + Cells).   
At 4 weeks, in vivo micro-CT showed that there was little mineral in the defect 
site.  No differences were observed between any groups and no effect of timing of 
delivery was detected (Figure 5.9).  In vivo micro-CT analysis at 8 weeks demonstrated 
that little to no bone formation occurs in the alginate hydrogels without BMP-2 (Figure 
5.10).  For immediate delivery samples, the addition of BMP-2 causes a significant 
increase in the bone volume over non-BMP-2 containing hydrogels.  The group with the 
most mineral at the 8 week time point is the immediate delivery group containing 1 
million cells.  This group was significantly greater than the BMP-2 and non-BMP-2 
containing hydrogels, as well as the delayed cell implantation group containing cells.  In 
several samples mineral is present throughout the defect site and is approaching a bridged 
defect.  Interestingly, delayed therapeutic implantation resulted in significantly less 
mineralization in the BMP-2 containing hydrogels and the BMP-2 with cells hydrogels.  
There were no significant differences observed between any of the groups for the delayed 
therapeutic delivery, and none of the defects were bridged by this time point. 
Similar results were observed at 12 weeks, albeit with elevated levels of bone 
volume compared to 8 weeks (Figure 5.11).  Again there was a significant increase in 
bone volume for hydrogels containing BMP-2 over non-BMP-2 containing hydrogels.   
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Figure 5.9   Radiographs and micro-CT reconstructions of immediate and delayed 
delivery hydrogels at 4 weeks post implantation. 
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Figure 5.10   Radiographs and micro-CT reconstructions of immediate and delayed 
delivery hydrogels at 8 weeks post implantation.  * p<0.05 significantly greater than 
No BMP, # p<0.05significantly greater than BMP, $p<0.05 significantly greater than 
delayed for that group. 
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Figure 5.11   Radiographs and micro-CT reconstructions of immediate and delayed 
delivery hydrogels at 12 weeks post implantation.  * p<0.05 significantly greater than 
No BMP, # p<0.05significantly greater than BMP, $p<0.05 significantly greater than 
delayed for that group. 
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Figure 5.12 Mean mineral density of newly formed bone in tested hydrogels at 4, 8 
and 12 weeks. 
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The immediately delivered hydrogel containing BMP-2 and cells had significantly greater 
bone volume than BMP-2 only and non-BMP-2 loaded hydrogels.  For the delayed 
samples, a significant effect of including cells and BMP-2 was observed over non-BMP-2 
loaded hydrogels.  However, this group still had significantly less mineral than the 
immediately delivered counterpart.  Analysis of the mean mineral density revealed no 
significant differences among any of the groups for any time point (Figure 5.12), 
indicating a similar level of bone maturity despite treatment or delivery time point. 
Histological Analysis 
H&E and Safranin-O staining of hydrogels lacking BMP-2 showed the presence 
of fibrous tissue along with remnants of alginate hydrogel.  No areas of mineralization 
were observed in the defect site for both the immediate and delayed samples for this 
group (Figure 5.13 and Figure 5.14).  For BMP-2 containing hydrogels, areas of mature 
bone were observed.  For both immediate and delayed samples, areas of alginate 
hydrogel were still observable after 12 weeks.  Interestingly, in cell loaded alginate 
hydrogels, the alginate has cells present in the hydrogel while acellular hydrogels lack 
cells (arrows in Figure 5.12 and Figure 5.13).  Most of these cells however do not stain 
for nuclei on H&E, suggesting the cells are no longer functional after 12 weeks.  Some 
cells are found along the surface of mineralized tissue, possibly indicating implanted cell 
bone formation. 
Immunohistochemistry for GFP showed very little positive staining, suggesting 
that by 12 weeks most of the implanted cells are no longer alive (Figure 5.14).  This 
confirms what is seen in the H&E and Safranin-O stains of cell loaded constructs, where  
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Figure 5.13 H&E staining of constructs after 12 weeks.  Cell loaded alginate 




Figure 5.14 Safranin-O staining of constructs after 12 weeks.  Cell loaded 
alginate hydrogels still showed the presence of cells after 12 weeks (arrows).  
Scale bar = 100 µm. 
 129 
 
Figure 5.15 Immunohistochemistry for GFP positive cells after 12 weeks in cell 
loaded alginate hydrogels.  Scale bar = 100 µm. 
 130 
the lack of nuclei suggest that the cells are no longer metabolically active.  Most of the 
cells visible in the H&E and Safranin-O stains did not stain positive for GFP. 
 
DISCUSSION 
The objective of this study was to examine the ability of stem cell loaded alginate 
hydrogels to regenerate bone tissue in a critically sized diaphyseal defect.  We first 
characterized empty defects to identify possible delayed delivery time points of the 
hydrogel to the defect. We found that by 7 days there was tissue infiltration but not total 
filling of the defect.  By day 14, the defect was nearly completely filled with host tissue.  
We next evaluated a percutaneous delivery approach to heal the defect.  It was 
determined that the blind, percutaneous injections resulted in inaccurate volume delivery 
to the defect site, hampering comparison of hydrogel groups.  The 14 day time point was 
initially chosen as one of the test groups lacked a hydrogel carrier, but this group failed to 
show robust bone formation in the defect site.  In addition, little bone formation was 
observed most likely due to the large amount of host tissue impeding robust 
mineralization spanning the defect site.  Finally, we adapted a delivery approach similar 
to the Masquelet technique where the defect site is reentered through the initial incision 
and the therapeutic delivered to the defect site.  Despite accurate delivery of the 
hydrogels in this technique, we observed a detrimental effect of delayed implantation 
compared to immediate implantation.  However, a beneficial effect of stem cell delivery 
was observed over acellular hydrogels at both time points.  Acellular samples 
consistently did not achieve bridging of the defect, while cell loaded constructs did 
achieve bridging of the defect in a majority of samples. 
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The characterization of empty defects revealed some interesting results about the 
host response to the volumetric bone loss.  As expected, there was a gradual increase in 
host tissue over time, with the defect being filled by 14 days.  Interestingly, by day 7 
there was a reduction in cancellous bone volume fraction in the proximal end of the 
defect site.  Conversely, there was an increase in bone volume fraction on the distal end.  
The two bone volume fractions remodeled to relatively the same level.  Histology further 
demonstrated that the tissue began to organize on the ends of the defect site.  It is well 
known that non-healing defects will undergo ‘end-capping’ where the periosteum forms 
cortical bone over the bone end.  Our data suggests that this process begins by 14 days 
with remodeling of the tissue adjacent to the defect site.  
Attempts to deliver stem cells to regenerate a tissue post injury have not been 
performed for orthopedic applications.  Limited studies have been performed for delayed 
progenitor cell delivery for neural tissue regeneration, restoring vascular supply in the 
brain (Kawabori, Kuroda et al. 2012, Kawabori, Kuroda et al. 2012).  However, most 
investigation into timing of delivery of mesenchymal stem cells has involved 
regeneration of cardiac muscle tissue due to damage from myocardial infarction.  Several 
clinical studies have investigated the use of mesenchymal stem cells to repair damaged 
muscle tissue due to myocardial infarct (Schachinger, Erbs et al. 2006, Schachinger, Erbs 
et al. 2006, Traverse, Henry et al. 2009, Traverse, Henry et al. 2010, Traverse, Henry et 
al. 2011).  Given the delicate state of patients following a myocardial infarction, 
researchers sought to determine whether harvesting of autologous mesenchymal stem 
cells two to three weeks from the infarct and injecting them into the left ventricular wall 
would have a benefit on heart function (Traverse, Henry et al. 2010).  It was reported that 
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delivery of 150 million autologous MSCs resulted in no added benefit in terms of ejection 
volumes from the left ventricular lobe (Traverse, Henry et al. 2010, Traverse, Henry et al. 
2011).  However, others have had success in giving stem cells to patients 5-7 days post 
infarct and seeing improvements in heart function (Schachinger, Erbs et al. 2006, 
Schachinger, Erbs et al. 2006).   These studies show that timing of delivery is critical in 
order to achieve a therapeutic effect.   
Our time points were chosen as we hypothesized the presence of endogenous 
tissue in the defect site may facilitate nutrient and waste exchange of the delivered stem 
cells, provide attachment sites for the cells as well as recruit more host progenitors before 
the BMP-2 could be degraded.  However, given our results, our delivery time may have 
been too late.  The amount of granular tissue in the defect site may have inhibited bone 
formation, and the BMP-2 may have been degraded by inflammatory cells at the defect 
site, limiting endogenous host cell recruitment.  In addition, during the second surgical 
procedure we did not clear the defect site of infiltrated tissue.  A possible consequence of 
this is limited space for the hydrogel at the 7 day time point, similar to what was observed 
in the 14 day delivery samples.  An alternative hypothesis is that immediate delivery of 
osteoinductive factors significantly affects the endogenous cells recruited to the defect 
site.  The mechanisms underlying our results need further study. 
As stated previously, we adapted a form of the Masquelet technique in order to 
relieve the need for graft materials by delivering biologics.  The Masquelet technique 
calls for a cement block in the defect site to prevent fibrous tissue invasion.  Our 
membrane was perforate, allowing tissue invasion.  We hypothesized that allowing some 
tissue infiltration into the defect would have a beneficial effect on our delivered biologics 
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thus leading to an increase in bone formation.  A true test of the Masquelet technique 
with our alginate hydrogel system may elucidate some of the shortcomings of our current 
approach which uses a synthetic membrane and allows host tissue infiltration.  For 
instance, comparison of the two techniques would allow for the effect of the granular 
tissue in the defect site on the delivered BMP-2 to be determined as well as any effect on 
delivered cell viability. 
 
SUMMARY 
In this study we demonstrated that inclusion of BMMSC into alginate hydrogels 
leads to greater bone formation in a non-healing diaphyseal defect compared to acellular 
hydrogels.  Empty defect characterization identified two potential time points for delayed 
delivery of therapeutics.  However, it was demonstrated that immediate delivery of the 
therapeutic results in more bone formation than a delayed time point of 7 days.  It should 
be noted that acellular constructs consistently did not achieve bridging of the defect, 
while cell loaded constructs had a majority of the samples with bridged defects.  These 
results may be attributable to a degradation of osteogenic factors by inflammatory cells 
present in the defect site at the delayed time point.  Alternatively, immediate delivery of 
osteoinductive factors may significantly affect the endogenous cells recruited to the 
defect site, resulting in greater bone formation long term. 
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CHAPTER 6: SUMMARY AND IMPLICATIONS  
 
SYNOPSIS 
Tissue engineering offers an attractive alternative to current clinical treatment 
methods as stem cells, polymer scaffolds, and growth factors can be delivered to provide 
short term benefit and promote a long term host response to heal critically sized defects.  
In particular, cell based therapies have the potential to alleviate the use of grafts from 
host tissue and allogeneic tissue sources.  In addition, co-delivery with growth factors 
could recruit host cells to a defect site as well as promote the differentiation of implanted 
cells.  These tools allow for a large assortment of potential strategies to address many 
developmental diseases and traumatic injuries. 
The goal of this thesis was to evaluate cell based tissue engineering strategies 
utilizing adult stem cells, growth factors, and hydrogels to regenerate bone tissue in vivo.  
We first evaluated adipose derived stem cells (ADSCs) as a potential cell source for bone 
tissue engineering (Chapter 3, Specific Aim I) by performing a rigorous examination of 
their osteogenic potential in 3-D.  We next tested two hydrogel systems, poly-ethylene 
glycol hydrogels and alginate hydrogels, as cell carriers for in vivo bone tissue 
engineering (Chapter 4, Specific Aim II).  We demonstrated that the alginate system 
supported robust in vivo bone formation when bone marrow mesenchymal stem cells 
(BMMSCs) were co-delivered with BMP-2.  Finally, we took what we learned from 
Specific Aim II and applied them in a critically sized diaphyseal defect in the femur of 
the rat.  We demonstrated that incorporation of bone marrow mesenchymal stem cells 
leads to greater in vivo bone formation than acellular hydrogels (Chapter 5, Specific Aim 
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III).    It was further demonstrated that immediate delivery of the hydrogel leads to a 
greater amount of bone formation than delaying the delivery of the therapeutic.  Taken 
together, we provide new insights into effective delivery strategies for cell based bone 
tissue engineering techniques. 
 
SPECIFIC AIM I 
The objective of this Specific Aim was to evaluate the osteogenic potential of 
ADSCs in order to utilize them in a bone defect model in vivo.  Adipose derived stem 
cells have the advantage of being more abundant than other stem cell sources, making 
them an attractive cell source for bone tissue engineering.  A summary of the results of 
tasks for this Specific Aim are provided below. 
Resveratrol Treatment of Rat ADSCs 
Resveratrol was identified as a potential pharmacological agent to increase the 
osteogenic potential of ADSCs.  The simultaneous suppression of PPAR-γ and 
stimulation of Runx-2 made resveratrol an ideal candidate to promote osteogenic 
differentiation of ADSCs.  2-D analysis of cells for the dose of resveratrol initially 
identified 25µM as an effective dose.  However, for tissue engineering the behavior of 
cells in a 3-D environment provides more insight into how they might perform in vivo.  
When we tested this with rat ADSCs in the 3-D PCL/collagen scaffold system, we 
observed an increase in mineralized matrix production at early time points.  Further, a 7 
day pre-treatment of the cells prior to seeding on the scaffold was shown to be sufficient 
to increase the mineralized matrix production compared to continuous treatment, which 
was not significantly higher than untreated cells.  When we later performed a dose 
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dependency study in 3-D using the pre-treatment regimen, we noted that lower doses of 
resveratrol than 25 µM resulted in greater mineralized matrix, particularly at later time 
points.  This is most likely due to increasing the early differentiation in higher doses, 
sacrificing proliferative capacity once seeded on the scaffolds.  However, for in vivo bone 
applications, the effect of cell delivery can be presumed to be early as the cells will 
function primarily as paracrine signaling agents.  We therefore chose to use the 12.5 µM 
dose for future in vivo studies. 
Resveratrol Treatment of Human ADSCs 
 Of interest for clinical applications, human ADSC osteogenic potential was also 
investigated using the resveratrol treatment regimen.  Dosage differences between 
hADSCs and rADSCs were observed.  In particular, the high dose of 25 µM has a 
detrimental effect on mineralized matrix production in 3-D for hADSCs.  When we 
performed a dose response, we observed similar results to rADSCs at lower doses, with a 
dose of 12.5 µM being the most effective at early time points, and 6.25 µM being the 
most effective at later time points.   
Comparison of rADSC and hADSC Mineralized Matrix 
 Histological and surface analysis demonstrated differences in the mineralized 
matrix produced by rADSCs and hADSCs.  rADSCs produced significantly more mineral 
than hADSCs in the 3-D culture environment.  Further, the mineralized matrix is more 
mature as rADSC had a higher mean mineral density than hADSC constructs.  
Differences in the maturity of the mineralized matrix were also observed over time, with 
the mean density increasing between time points.  Also observed was a difference in the 
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cellularity of the mineralized matrix.  hADSCs had areas of high cellularity, while 
rADSCs had much larger nodules of mineral.   
Concurrent Treatment of Resveratrol and BMP-2 
 As delivery of BMP-2 has been shown to be necessary to induce ADSC 
differentiation in vivo, the concurrent treatment of resveratrol and BMP-2 on rADSC 
mineralized matrix production was evaluated.  We observed that the short 48 hour 
treatment of BMP-2 resulted in no added benefit in terms of mineralized matrix 
production.  This is most likely attributable to the long culture time and 4 week span from 
the end of the BMP-2 treatment until the measurement of the mineralized matrix via 
micro-CT.  By this time, the duration of culture in osteogenic media is most likely the 
dominant driver of mineralization.  This assumption is supported by our 2-D alkaline 
phosphatase data, which showed BMP-2 treatment caused a significant increase in ALP 
activity at the shorter 14 day time point. 
Implications 
 Taken together, these data imply that rADSCs are more osteogenic than hADSCs 
resulting in a greater amount of 3-D mineralized matrix production.  These differences 
may be due to a higher metabolic activity than hADSCs.  As such, rat derived stem cells 
were chosen as the cell source for future experiments.  The short exposure time of BMP-2 
may have been insufficient to detect an effect of BMP-2 treatment of ADSCs.  A future 
study in which multiple short BMP-2 exposure times are used may lead to increased 
mineralized matrix, and may be a more accurate assessment of the effect of BMP-2 in 
long term cultures.  Further, concurrent treatment of hADSCs with BMP-2 and 
resveratrol may increase their mineralized matrix production in the 3-D PCL/collagen 
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system.  It would provide insight into the role of BMP-2 to test for the osteogenic gene 
expression of the cells in the 3-D culture system at early time points as well. 
 
SPECIFIC AIM II 
The objective of this Specific Aim was to evaluate hydrogels as an injectable cell 
delivery vehicle for bone tissue engineering.  PEG and alginate based hydrogels were 
examined for their in vitro cell viability and in vivo bone formation in a subcutaneous 
ectopic mineralization model.  A summary of the results of tasks for this Specific Aim are 
provided below. 
In vitro Cell Viability in PEG Hydrogels 
Using the PEG-DA hydrogel system, we observed that breaking up the hydrogel 
via injection resulted in greater cell viability than traditionally molded hydrogels.  
Further, incorporation of the cell attachment peptide RGD sustained greater cell viability 
at 14 days.  Similar levels of cell viability were observed between ADSCs and BMMSCs.  
The APS/TEMED cross-linking system may have had a detrimental effect on the cell 
viability, as this system generates free radicals to cross-link the acrylate groups on the 
PEG backbone.     
PEG Hydrogels as a Cell Delivery Vehicle for Bone Tissue Engineering 
When implanted subcutaneously into RNU Nude rats, we observed very little 
ectopic mineralization in all of our groups.  Incorporation of 2 µg of BMP-2 had no effect 
on the mineralized matrix production in the hydrogels.  Micro-CT reconstructions 
showed that the ectopic mineralization that did occur was located primarily on the ends or 
the periphery of the implanted construct.  Histological analysis showed the presence of 
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hydrogel still in the mesh tube, inhibiting new tissue formation.  Few implanted cells 
were detected via immunohistochemistry, suggesting that any mineralization observed 
was endogenous cell driven.   
In vitro Cell Viability in Alginate Hydrogels 
Irradiated and oxidized irradiated alginate hydrogels were assessed for their in 
vitro cell viability.  24 hours after encapsulation, ADSC and BMMSC oxidized-irradiated 
hydrogels had lower cell viability than irradiated hydrogels. This is most likely due to the 
oxidized-irradiated hydrogels being more acidic, as noted by change in the phenol red 
indicator in α-MEM.  By 7 days, all groups had similar cell viability.  Analysis of the 
DNA content of the hydrogels showed that for all cell types there was an increase in cell 
number at 7 and 14 days.  Compared to the PEG-DA hydrogel system, the alginate 
system had significantly greater cell viability at 14 days.  These results suggest that 
alginate hydrogels are a viable cell delivery vehicle for an injectable bone tissue 
engineering system. 
Degradation Kinetics of Irradiated and Oxidized Irradiated Alginate Hydrogels 
The wet weight degradation of the two alginate based hydrogel systems was 
evaluated.  Both hydrogels exhibited a similar degradation rate in vitro, and no significant 
differences in the amount of hydrogel left were detected until day 14.  No differences 
were observed by incorporating cells into the hydrogel.  At day 14, the oxidized-
irradiated hydrogels had a significantly higher amount of mass loss compared to 
irradiated hydrogels.  As the cells were cultured in standard growth media and remained 
undifferentiated, the cells were not induced to degrade the material.  As such, the lack of 
major differences in the system are likely attributable to the culture conditions.  Given the 
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similar degradation kinetics and cell viability, the irradiated alginate system was chosen 
as the hydrogel to test for in vivo bone formation. 
Alginate Hydrogels as a Cell Delivery Vehicle for Bone Tissue Engineering 
 The irradiated alginate hydrogel system was investigated as an injectable cell 
delivery system for bone tissue engineering using a subcutaneous ectopic mineralization 
model.  Micro-CT reconstructions and quantification demonstrated that ADSC loaded 
hydrogels had significantly less mineralized matrix relative to acellular hydrogels.  This 
is most likely due to the ADSCs not secreting osteoinductive factors to promote bone 
formation from endogenous cells.  Conversely, BMMSC inclusion resulted in a 
significant increase in bone formation compared to acellular hydrogels.  This increase 
over acellular hydrogels suggests that the BMMSCs are producing osteoinductive factors 
that are promoting endogenous bone formation.  This is further supported by only 50% of 
the acellular hydrogels producing robust mineralization, with the samples that did not 
mineralize likely not having enough BMP-2 still active in the hydrogel by the time host 
cells invaded the hydrogel.  Histological analysis of explants showed that some implanted 
cells were still present in the constructs; however the majority of cells were host-derived 
cells.   
Implications  
 The lack of mineralized tissue in the PEG system is most likely due to the non-
resorption of the material.  Future studies should incorporate enzymatically degradable 
cross-links, which will facilitate degradation of the material.  This will result also in the 
presentation of more active growth factor, as the material will be broken down exposing 
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the BMP-2.  As such, greater bone formation should be observed compared to the PEG-
DA system. 
 The lack of mineralization in the ADSC groups in alginate hydrogels, and the 
robust mineralization of BMMSC loaded hydrogels, demonstrates that there is an effect 
of the type of cells on the bone formation response.  We hypothesize that this is due to 
paracrine signaling and stimulation of endogenous progenitor cell differentiation.  To 
evaluate this, it would be interesting to look at osteogenic protein expression of the 
implanted stem cells within the first 7 days of being implanted.  Further, characterization 
of cells initially recruited to the hydrogel compared to non-BMP-2 containing gels might 
elucidate the dichotomy in the acellular hydrogel results. 
 
SPECIFIC AIM III 
The objective of this Specific Aim was twofold: 1) evaluate the ability of an 
injectable stem cell loaded alginate hydrogel to heal a critically sized femoral defect, and 
2) assess the effect of timing of delivery of therapeutics for bone formation in the femoral 
defect.  A summary of the results of tasks for this Specific Aim are provided below. 
Characterization of Empty Defects 
 We first characterized empty segmental defects in terms of host tissue infiltration.  
As expected, we observed a gradual filling of the defect space when left empty over a 14 
day time course.  By day 14, the entire defect was filled with granular tissue.  
Macrophage presence was detected by day 3, however a larger presence was observed at 
days 7 and 14.  The majority of the cells present in the defect site were 
polymorphonuclear cells (PNCs), indicative of neutrophils.  These results suggest that the 
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inflammation response proceeds over the entire 14 day time course.  Organization of the 
tissue adjacent to the bone ends was observable at day 14, indicative of the initiation of 
the bone ‘end-capping’ process in non-healing defects.  Micro-CT analysis of the 
cancellous bone in the medullary cavity adjacent to the defect site suggested that the bone 
ends quickly remodel due to the creation of the defect.  On the proximal end, there was a 
significant decrease in cancellous bone volume fraction.  For the distal end, a significant 
increase in the cancellous bone volume fraction was observed, with both ends remodeling 
to a similar bone volume fraction.  
Percutaneous Delivery of Injectable Alginate Hydrogels 
Given our results with the empty defect characterization, we first attempted a 
percutaneous delivery approach with an immediate implantation of therapeutics and a 
delayed implantation at 14 days.  The 14 day time point also allowed us to test delivery of 
cells and BMP-2 without a hydrogel carrier, as the host tissue would allow for 
engraftment of the cells.  Unfortunately, blindly delivering the therapeutics to the defect 
site resulted in inaccurate delivery of the hydrogel, making quantitative comparisons 
unreasonable.  However, with the micro-CT reconstructions some qualitative assessment 
of the bone formation in the limbs could be made.    
For the immediate injection, all 5 of the cell loaded alginate hydrogels 
mineralized with 4 mineralizing ectopically in the surrounding muscle and the 1 sample 
delivered accurately mineralizing in the defect site.  For cell free hydrogels, 3 out of 5 
produced mineral all of which were ectopic in the surrounding muscle.  This rate of 
mineralization for these two groups agrees with what was observed in the subcutaneous 
model for the groups respectively as discussed in Specific Aim II.  For the carrier free 
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group, none of the samples mineralized ectopically or in the defect site.  For one sample 
there was some mineralization along the mesh.  The lack of mineralization is most likely 
due to ambulation of the limb resulting in dispersion of the therapeutic since there is no 
hydrogel to retain the cells and BMP-2 in the injection site. 
With more experience in delivering the hydrogels blindly, the delayed delivery 
hydrogels were delivered closer to the defect site.   However in some samples part of the 
hydrogel ended up outside the nanofiber mesh.  Results demonstrate that for the acellular 
constructs the mineralization response appears to be less than what was observed with 1 
µg of BMP-2 in previous studies in our lab (Boerckel, Kolambkar et al. 2011).  This is 
possibly due to failure of delivery of the entire 150 µL to the defect site and also the 
presence of host tissue retarding the ability of the hydrogel and BMP-2 to form a 
continuous volume of bone.  For cell loaded constructs, there appears to be a similar 
amount of bone formation compared to the acellular constructs.  For the carrier free 
group, there appears to be little bone formation in any samples.  Like the immediate 
injection results for this group, ambulation of the limb may be resulting in dispersion of 
the therapeutic following injection.   
Immediate versus Delayed Bone Formation with 2
nd
 Procedure 
Accuracy of delivery prevented quantification of differences in the groups tested, 
however we were able to discern that the group lacking hydrogel is ineffective for bone 
formation, as well as the 14 day time point being too late to deliver 150 µL of hydrogel 
into the defect site.  Future studies using a portable MRI system could improve the 
accuracy of delivery of the hydrogel percutaneously.  However, due to resources we 
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altered the surgical procedure to allow for the defect site to be visible to ensure accurate 
delivery, and further moved up our delayed time point to 7 days.   
At 4 weeks, in vivo micro-CT showed that there was little mineral in the defect 
site.  No differences were observed between any groups and no effect of timing of 
delivery was detected.  In vivo micro-CT analysis at 8 weeks demonstrated that little to 
no bone formation occurs in the alginate hydrogels without BMP-2 as expected.  For 
immediate delivery samples, the addition of BMP-2 causes a significant increase in the 
bone volume over non-BMP-2 containing hydrogels.  The group with the most mineral at 
the 8 week time point is the immediate delivery group containing 1 million BMMSCs.  
This group was significantly greater than the BMP-2 and non-BMP-2 containing 
hydrogels, as well as the delayed cell implantation group containing cells.  Interestingly, 
delayed therapeutic implantation resulted in significantly less mineralization in the BMP-
2 containing hydrogels and the BMP-2 with cells hydrogels.  There were no significant 
differences observed between any of the groups for the delayed therapeutic delivery, and 
none of the defects were bridged by this time point.  Similar results were observed at 12 
weeks, albeit with elevated levels of bone volume compared to 8 weeks.   
Histological Analysis of Bone Formation and Implanted Cell Presence 
H&E and Safranin-O staining of hydrogels lacking BMP-2 showed the presence 
of fibrous tissue along with remnants of alginate hydrogel for both the immediate and 
delayed samples.  No areas of mineralization were observed.  BMP-2 containing 
hydrogels demonstrated areas of mature bone were observed.  For both immediate and 
delayed samples, areas of alginate hydrogel were still observable after 12 weeks.  
Interestingly, in cell loaded alginate hydrogels, the alginate has cells present in the 
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hydrogel while acellular hydrogels lack cells.  Most of these cells however do not appear 
to be functional after 12 weeks.  Some cells are found along the surface of mineralized 
tissue, possibly indicating implanted cell bone formation.  Immunohistochemistry for 
GFP showed very little positive staining, suggesting that by 12 weeks most of the 
implanted cells are no longer alive. 
Implications  
Our results, in terms of timing of delivery, suggest that the presence of BMP-2 
early in the defect site may play a role in the types of cells initially recruited.  It would be 
interesting to characterize the populations of cells recruited by placing a BMP-2 and non-
BMP-2 loaded alginate hydrogel into the defect site.  The presence of BMP-2 early may 
also have implications in terms of the vascular progenitor cells recruited as well, and this 
may ultimately impact bone formation.   
As stated previously, we adapted a form of the Masquelet technique in order to 
relieve the need for graft materials by delivering biologics.  The Masquelet technique 
calls for a cement block in the defect site to prevent fibrous tissue invasion.  Our 
membrane was perforated, allowing tissue invasion as we hypothesized that allowing 
some tissue infiltration into the defect would have a beneficial effect on our delivered 
biologics thus leading to an increase in bone formation.  A true test of the Masquelet 
technique with our alginate hydrogel system may elucidate some of the shortcomings of 
our current approach in using a synthetic membrane and allowing host tissue infiltration.  
For instance, comparison of the two techniques would allow us to determine the effect of 
the granular tissue in the defect site on the delivered BMP-2 as well as any effect on 
delivered cell viability.   
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CONCLUSIONS 
A cell based tissue engineering approach for bone regeneration was developed in 
this thesis.  We demonstrated that despite the increase in osteogenic potential of ADSC in 
vitro via resveratrol treatment, in vivo bone formation utilizing ADSCs is minimal.  In 
contrast, the incorporation of BMMSCs results in robust bone formation in vivo.  This 
was demonstrated in an injectable hydrogel system in an ectopic mineralization model.  
The creation of an injectable cell delivery system allowed us to evaluate temporal effects 
of therapeutic delivery.  We demonstrated a temporal effect of delivery of the 
therapeutics into a segmental bone defect, in which delayed implantation results in less 
bone formation than immediate implantation.  Taken together, we demonstrate that 
incorporation of adult stem cells into an injectable hydrogel is a viable system to promote 
repair of clinically challenging bone defects. 
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CHAPTER 7: FUTURE DIRECTIONS 
The objective of this thesis was to evaluate the utility of adult stem cells for bone 
tissue engineering.  Briefly, we first established an enrichment protocol for adipose 
derived stem cells that increases their mineralized matrix production in vitro.  We next 
evaluated the potential of adipose derived stem cells and bone marrow mesenchymal 
stem cells to produce mineralized tissue in both ectopic and orthotopic sites via a 
biologically functionalized hydrogel.  Our results demonstrate that adipose derived stem 
cells are inferior to bone marrow mesenchymal stem cells for in vivo bone tissue 
engineering.  We further investigated the effect of delivery time on the amount of bone 
regeneration in a non-healing bone defect model.  It was demonstrated that delayed 
delivery results in reduced bone formation compared to immediate delivery of the 
therapeutic.  Taken together, this raises several questions about effective cell based tissue 
engineering strategies for bone regeneration. 
Role of Cells 
 Our results show that adipose derived stem cells are able to form mineralized 
matrix in vitro when cultured in osteogenic media.  Further, pre-treatment with 
resveratrol increases the mineralized matrix production in a 3-D culture environment.  
However, pre-treatment with resveratrol is insufficient to promote robust mineralization 
in vivo, even with the co-delivery of the potent osteoinductive factor BMP-2.  This 
suggests that ADSCs require a large osteogenic stimulus to produce mineralized tissue.  
One way to possibly increase the in vivo mineralization potential of ADSCs in our 
hydrogel system would be to incorporate both undifferentiated ADSCs and osteogenic 
differentiated ADSCs into the same construct.  Park demonstrated that ADSCs cultured 
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in osteogenic media on PLGA scaffolds for 4 weeks are able to regenerate a tibial defect 
(Park, Zhou et al. 2012).  Just as important as mineralized matrix production is the ability 
to revascularize a defect site.  Undifferentiated ADSCs have been shown to have positive 
effects on angiogenesis in vivo (Mazo, Hernández et al. 2012).  As such, incorporation of 
both osteogenic differentiated and undifferentiated ADSCs may improve bone formation 
in the hydrogel system.  This could first be studied in the ectopic mineralization model to 
analyze dosages of differentiated and undifferentiated cells in order to identify optimal 
concentrations for mineralized tissue production.  
As stated previously, the dichotomy of results between ADSC groups in alginate 
hydrogels and BMMSC loaded hydrogels demonstrates that there is an effect of the type 
of cells implanted on the bone formation response in vivo.  We hypothesize that this is 
due to paracrine signaling and stimulation of endogenous progenitor cell differentiation.  
To evaluate this, the osteogenic protein expression of the implanted stem cells within the 
first 7 days of implantation could be evaluated.  Our results further demonstrate that 
endogenous cell recruitment is vital to robust bone formation.  Characterization of cells 
initially recruited to hydrogels containing BMP-2 compared to non-BMP-2 containing 
gels would provide insight into early cytokine signaling and host cell recruitment to the 
hydrogel.  Identification of differences in cell recruitment could potentially provide 
therapeutic targets to increase the retention of circulating osteoprogenitors to the 
mineralization site. 
Role of the Cell Carrier 
 In Specific Aim I, we used a PCL/collagen system to evaluate the osteogenic 
potential of ADSCs.  It was later shown that while this system has utility in vitro, its 
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application for in vivo applications is limited (Appendix A).  It was further shown that 
cells seeded onto PCL nanofiber meshes and implanted into the segmental defect results 
in cell death within the first 72 hours.   These results demonstrated the need for a cell 
carrier that would facilitate cell viability in vivo. 
 In Specific Aim II, we investigated PEG and alginate based hydrogels for in vitro 
cell viability and in vivo bone formation.  Both systems showed they sustained cell 
viability in vitro over a 14 day time course, with alginate having a higher degree of 
viability compared to PEG based systems.  The lack of mineralized tissue in the PEG 
system is most likely due to the non-resorption of the material.  Incorporation of 
enzymatically degradable cross-links will facilitate greater degradation of the material.  
As such, the presentation of more active growth factor would occur as the material will 
be broken down exposing the BMP-2.  Thus greater bone formation should be observed 
compared to the PEG-DA system.  In Specific Aim II and Specific Aim III, alginate 
hydrogels supported robust bone formation in vivo when coupled with BMP-2 and 
BMMSCs.  In the segmental defect, histological analysis demonstrated that large pockets 
of hydrogel are still present in the defect site at 12 weeks.   
Taken together, these results show that the method of delivery of cells is an 
important criterion for successful bone tissue engineering strategies.  Further, degradation 
of the hydrogel is necessary for new tissue formation.  Oxidation of the alginate back 
bone has been shown to increase the degradation rate of the hydrogel (Bouhadir, Lee et 
al. 2008).  Oxidizing the back bone may result in greater degradation of the hydrogel, 
allowing for greater new bone formation in the defect site.  A second strategy may be to 
lower the weight percentage of the alginate hydrogel.  However, the retention of the cells 
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and BMP-2 are necessary for robust bone formation, as constructs lacking hydrogel did 
not mineralize in vivo.  As such, a study looking at different weight percentages of 
alginate hydrogels is likely to show a positive effect of the reduction in alginate weight 
percentage until the hydrogel is unable to retain shape and leaks out of the defect space.  
Finally, another strategy of further irradiating the alginate backbone to reduce the 
molecular weight of the alginate hydrogel chains may also facilitate greater degradation.  
The average molecular weight of our alginate was 50 kDa.   Lowering the weight 
percentage should provide greater degradation kinetics ultimately leading to greater bone 
formation in vivo. 
Role of Timing of Delivery 
We demonstrated in Specific Aim III that delayed implantation of therapeutics 
results in reduced bone formation in a non-healing bone defect.  This suggests that the 
presence of BMP-2 early in the defect site may play a role in the types of cells initially 
recruited.  As stated previously, it would be interesting to characterize the populations of 
cells recruited by placing a BMP-2 and non-BMP-2 loaded alginate hydrogel into the 
defect site.  The presence of BMP-2 early may also have implications in terms of the 
vascular progenitor cells recruited to the defect site as well, and this may ultimately 
impact the regenerative capacity of the defect.   
 In order to accurately deliver the hydrogel, we had to implement a two-step 
surgical procedure that allowed the defect site to be visible to the surgeon.  It is possible 
that the second surgery is having a detrimental effect on the healing response.  Adopting 
a purely percutaneous approach by using a portable MRI machine to ensure accurate 
delivery of the therapeutic to the defect site  would bypass the need for the second 
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procedure.  This may produce a better result than our two-step surgical procedure and 
warrants further study.   
Mimicking a Clinical Situation 
   An experiment that may mimic clinical procedures would be to use the 
Masquelet technique discussed previously to place a spacer into a bone defect site.  At the 
same time, autologous stem cells from the bone marrow can be harvested in the 
contralateral femur.  After expansion of the cells in vitro, simultaneously allowing growth 
of the membrane surrounding the spacer in vivo, the autologous cells could then be 
delivered in a hydrogel and bone formation could be assessed.  A large animal model, 
such as in sheep or goats, would also provide insight into the scale-up ability of the 
hydrogel system and the amount of cells needed for a clinical application.  These would 
be powerful experiments to test the use of autologous cells for large diaphyseal bone 
defect regeneration.   
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APPENDIX A:  MOTIVATION FOR ADOPTING HYDROGELS AS A CELL 
DELIVERY VEHICLE 
 Prior to adopting the hydrogel approach to deliver stem cells, we first evaluated 
the PCL/Collagen system as a delivery vehicle for stem cells in vivo.  3 million untreated 
and resveratrol pre-treated rat ADSCs were seeded onto the PCL/Collagen scaffold as 
described in Chapter 3.  The constructs were cultured overnight in growth media, and 
then implanted into a segmental bone defect as described in Chapter 5. 
 Micro-CT quantification of mineralized matrix showed virtually no bone 
formation within the scaffold.  Nearly all bone formation that was in the defect site was  
 
due to the periosteal response.  End-capping of the bone was observed indicating that the 
physiologic response of our implants was similar to a non-union. 
This study was followed up by seeding 1 million GFP ADSCs onto a PCL 
nanofiber mesh tube and implanting them into the defect site.  The meshes were then 
explanted and imaged for GFP cells after 3 days.  Our results showed that we had high 
Figure A.1.  Ex vivo Micro-CT reconstruction of ADSCs seeded on 
PCL/Collagen scaffolds and implanted into the segmental defect after 12 weeks. 
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cell viability on the mesh tubes prior to implantation.  When explanted and examined 
after 3 days, almost all of the cells were no longer visible on the mesh (Figure A.2).  
This indicated that having the cells readily exposed to the implant environment 
such as in the case of the PCL/Collagen scaffold may have a detrimental effect on the 
bone regeneration potential of implanted cells.  We therefore chose to investigate 
hydrogels, as the hydrogel would offer some protection of the implanted cells from the 
initial host response, as well as facilitate diffusion of nutrients and waste products due to 
their high water content.   
Figure A.2.  GFP ADSC presence prior (B) and after (C) implantation into a 
segmental defect for 3 days. Scale Bar = 500 µm. 
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APPENDIX B:  STABILITY OF GFP SIGNAL IN ADSCs and 
BMMSCs 
Given the need to be able to track cell survival in vivo, we isolated adipose derived stem 
cells and bone mesenchymal stem cells from genetically modified rats that ubiquitously 
express green fluorescent protein (GFP).  Characterization of GFP ADSCs showed that 
the cells were highly proliferative, with as many as 18 doublings through 8 passages (data 
not shown).  We further characterized the cell source in terms of the amount of green 
fluorescent protein expressed through multiple passages.  Qualitative analysis showed 
that the GFP signal was easily detectable, and further that the GFP signal was stable over 
multiple passages and cell doublings (Fig. B.1). This is an important criterion as it 
ensures that we will be able to track the cells ex vivo via fluorescent microscopy allowing 
us to detect cell survival after implantation.  Bone marrow mesenchymal stem cells 
demonstrated similar results in terms of proliferation as well as stable GFP expression 
over multiple passages. 
  
Figure B.1.  Fluorescence of GFP ADSCs and BMMSCs through 8 passages and 18 
doublings.  
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Figure C.1.  Solid Works drawings of modified internal fixation plate to allow 
percutaneous delivery of hydrogels.  
APPENDIX C:  MODIFIED FIXATION PLATE DRAWINGS TO 
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